

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 39/09, 39/40, A61P 31/04 // C07K 14/315</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/37105</b> <b>(43) International Publication Date:</b> 29 June 2000 (29.06.00)
<b>(21) International Application Number:</b> PCT/US99/30390 <b>(22) International Filing Date:</b> 21 December 1999 (21.12.99) <b>(30) Priority Data:</b> 60/113,048 21 December 1998 (21.12.98) US <b>(71) Applicant:</b> MEDIMMUNE, INC. [US/US]; 35 West Watkins Mill Road, Gaithersburg, MD 20878 (US). <b>(72) Inventors:</b> JOHNSON, Leslie, S.; 13545 Ambassador Drive, Germantown, MD 20874 (US). KOENIG, Scott; 10732 Ralston Road, Rockville, MD 20852 (US). ADAMOU, John, E.; 20822 Shamrock Glen Circle, Germantown, MD 20874 (US). <b>(74) Agents:</b> GRANT, Alan, J. et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> STREPTOCOCCUS PNEUMONIAE PROTEINS AND IMMUNOGENIC FRAGMENTS FOR VACCINES  <b>(57) Abstract</b>  A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by <i>S. pneumoniae</i> comprising administering of vaccine compositions.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# STREPTOCOCCUS PNEUMONIAE PROTEINS AND IMMUNOGENIC FRAGMENTS FOR VACCINES

5

This application is based on U.S. Provisional Application No. 60/113,048, filed 21 December 1998, which is hereby incorporated in its entirety.

10

## FIELD OF THE INVENTION

This invention relates generally to the field of bacterial antigens and their use, for example, as immunogenic agents in humans and animals to stimulate  
15 an immune response. More specifically, it relates to the vaccination of mammalian species with a polypeptide comprising at least one conserved histidine triad residue (HxxHxH) and at least one helix-forming polypeptide obtained from *Streptococcus pneumoniae* as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by  
20 a wide range of serotypes of pathogenic *S. pneumoniae*. Further, the invention relates to antibodies against such polypeptides useful in diagnosis and passive immune therapy with respect to diagnosing and treating such pneumococcal infections.

25 In a particular aspect, the present invention relates to the prevention and treatment of pneumococcal infections such as infections of the middle ear, nasopharynx, lung and bronchial areas, blood, CSF, and the like, that are caused by pneumococcal bacteria.

## BACKGROUND OF THE INVENTION

*Streptococcus pneumoniae* is a gram positive bacteria which is a major causative agent in invasive infections in animals and humans, such as sepsis, meningitis, otitis media and lobar pneumonia (Tuomanen et al. *New Engl. J. Med.* **322**:1280-1284 (1995)). As part of the infective process, pneumococci readily bind to non-inflamed human epithelial cells of the upper and lower respiratory tract by binding to eukaryotic carbohydrates in a lectin-like manner (Cundell et al., *Micro. Path.* **17**:361-374 (1994)). Conversion to invasive pneumococcal infections for bound bacteria may involve the local generation of inflammatory factors which may activate the epithelial cells to change the number and type of receptors on their surface (Cundell et al., *Nature*, **377**:435-438 (1995)). Apparently, one such receptor, platelet activating factor (PAF) is engaged by the pneumococcal bacteria and within a very short period of time (minutes) from the appearance of PAF, pneumococci exhibit strongly enhanced adherence and invasion of tissue. Certain soluble receptor analogs have been shown to prevent the progression of pneumococcal infections (Idanpaan-Heikkila et al., *J. Inf. Dis.*, **176**:704-712 (1997)). A number of various other proteins have been suggested as being involved in the pathogenicity of *S. pneumoniae*. There remains a need for identifying polypeptides having epitopes in common from various strains of *S. pneumoniae* in order to utilize such polypeptides as vaccines to provide protection against a wide variety of *S. pneumoniae*.

25

## SUMMARY OF INVENTION

In accordance with the present invention, there is provided vaccines and

vaccine compositions that include polypeptides obtained from *S. pneumoniae* and/or variants of said polypeptides and/or active fragments of such polypeptides.

- 5           The active fragments, as hereinafter defined, include a histidine triad residue(s) and/or coiled coil regions of such polypeptides.

10           The term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence from an alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The percent identity is determined as follows:

$$\text{Percent Identity} = [1 - (C/R)] 100$$

15           wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of the alignment between the Compared Sequence and the Reference Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have an aligned base or  
20           amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, each being a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared  
25           Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

          If an alignment exists between the Compared Sequence and the Reference Sequence in which the Percent Identity as calculated above is about

equal to or greater than a specified minimum Percent Identity than the Compared Sequence has the specified minimum Percent Identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.

"Isolated" in the context of the present invention with respect to polypeptides and/or polynucleotides means that the material is removed from its original environment (*e.g.*, the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living organism is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment. The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

## BRIEF DESCRIPTION OF DRAWINGS

Figures 1A-1C, respectively, report the results of three experiments using different preparations of SP36. The results demonstrate that active immunization with recombinant SP36 derived from pneumococcal strain Norway serotype 4 is able to protect mice from death in a model of pneumococcal sepsis using a heterologous strain, SJ2 (serotype 6B). In each of the three experiments shown, one hundred percent of the mice immunized

with SP36 survived for the 14-day observation period following challenge with approximately 500 cfu of pneumococci, while eighty to one hundred percent of sham-immunized mice (injected with PBS and adjuvant) died during the same period.

5

Figures 2A-2B show that passive administration of rabbit antiserum raised against Sp36 derived from Norway type 4 was able to protect mice in the pneumococcal sepsis model using two heterologous strains. Figure 2A shows that one hundred percent of the mice immunized with the SP36 antiserum survived the 21-day observation period after challenge with 172 CFU of strain SJ2 (serotype 6B). Eighty percent of the mice immunized with a control serum (rabbit anti-FimC) died by day 8, and ninety percent died by day 12. Figure 2B shows that 90 percent of the mice immunized with the Sp36 antiserum survived the 8-day observation after challenge with 862 CFU of strain EF6796 (serotype 6A). Ninety percent of the mice immunized with a control serum (collected before immunization) died by day 5.

Figure 3 is a western blot demonstrating the ability of antisera raised against recombinant Sp36 derived from strain Norway type 4 to react with Sp36 of heterologous strains. Total cell lysates were immunoblotted with mouse antisera to Sp36. A band representing Sp36 protein was detected in all 23 *S. pneumoniae* strains tested, which included isolates from each of the 23 pneumococcal serotypes represented in the current polysaccharide vaccine.

Figure 4 is a Southern blot showing that the Sp36 gene from Norway type 4 hybridizes with genomic DNA from 24 other pneumococcal strains, indicating the presence of similar sequences in all these strains.

Figure 5 is a western blot showing the reactivity of patient sera with Sp36. Sp36 (either full-length, panel A; N-terminal half, panel B; or C-terminal half, panel C) was electrophoresed by SDS-PAGE and transferred to nitrocellulose. Patient sera collected soon after the onset of illness (acute serum, lanes A) or eight to 30 days later (convalescent serum, lanes C) were used to probe the blots. For patients 2, 3, and 5, convalescent serum reacted more strongly with Sp36 than did the corresponding acute serum.

Figure 6 is an amino acid alignment comparison of four related pneumococcal proteins, namely Sp36A (PhtA; SEQ ID NO:8), Sp36B (PhtB; SEQ ID NO:10), Sp36D (PhtD; SEQ ID NO:4), Sp36E (PhtE; SEQ ID NO:6), respectively. Dashes in a sequence indicate gaps introduced to maximize the sequence similarity. Amino acid residues that match are boxed.

Figure 7 is a nucleotide alignment comparison of four related pneumococcal genes, namely Sp36A (PhtA; SEQ ID NO:9), Sp36B (PhtB; SEQ ID NO:11), Sp36D (PhtD; SEQ ID NO:5), Sp36E (PhtE; SEQ ID NO:7), respectively. Dashes in a sequence indicate gaps introduced to maximize the sequence similarity.

Figure 8 shows the results of immunization of mice with PhtD recombinant protein, which leads to protection from lethal sepsis. C3H/HeJ (Panel A and B) or Balb/cByJ (Panel C) mice were immunized subcutaneously with PhtD protein (15 µg in 50 µl PBS emulsified in 50 µl complete Freund's adjuvant (CFA)). The recombinant PhtD protein used in protection experiments consisted of 819 amino acid residues, starting with the cysteine



(residue 20). A group of 10 sham-immunized mice received PBS with adjuvant. A second immunization of 15  $\mu$ g protein with incomplete Freund's adjuvant (IFA) was administered 3 weeks later; the sham group received PBS with IFA. Blood was drawn (retro-orbital bleed) at week 7; and sera from  
5 each group was pooled for analysis of anti-PhtD antibody by ELISA. Mice were challenged at week 8 by an intraperitoneal (i.p.) injection of approximately 550 CFU *S. pneumoniae* strain SJ2, serotype 6B (Panel A), 850 CFU of strain EF6796, serotype 6A (Panel B) or 450 CFU of strain EF5668, serotype 4 (Panel C). In preliminary experiments, the LD<sub>50</sub> for strain  
10 SJ2 and EF6796 were determined to be approximately 10 CFU for both strains. The LD<sub>50</sub> for strain EF5668 was determined to be < 5 CFU. Survival was determined in all groups over the course of 15 days following challenge. Data are presented as the percent survival for a total of 10 mice per experimental group. Two-sample Log-rank test was used for statistical  
15 analysis comparing recombinant Pht immunized mice to sham-immunized mice.

## SUMMARY OF THE INVENTION

20

In accordance with one aspect of the present invention, there is provided a vaccine, generally in the form of a composition, that includes at least one polypeptide that is at least 90% identical to (c) a polypeptide

sequence comprising amino acids 1-819 of SEQ ID NO:4 or (ii) a polypeptide sequence comprising amino acids 1-460 of SEQ ID NO:6 or an active fragment of the foregoing.

5           In accordance with another aspect of the present invention, there is provided a vaccine, generally in the form of a composition, that includes an active fragment of a polypeptide that is at least 90% identical to (i) a polypeptide comprising amino acids 1-800 of SEQ ID NO:8 or (ii) a polypeptide comprising amino acids 1-800 of SEQ ID NO:10.

10

The term "active fragment" means a fragment that includes one or more histidine triad residues and/or one or more coiled coil regions. A "histidine triad residue" is the portion of the polypeptide that has the sequence HxxHxH wherein H is histidine and x is an amino acid other than histidine

15

A coiled coil region is the region predicted by "Coils" algorithm: Lupas, A., Van Dyke, M., and Stock, J. (1991) Predicting Coiled Coils from Protein Sequences, *Science* 252:1162-1164.

20           In accordance with one embodiment, the active fragment includes both one or more histidine triad residues and at least one coiled coil region of the applicable polypeptide sequence. In accordance with another embodiment, the active fragment includes at least two histidine triad residues.

25           In another embodiment, the active fragment that includes at least one histidine triad residue or at least one coiled-coil region of the applicable polypeptide includes at least about ten percent of the applicable polypeptide and no more than about 85% of the applicable polypeptide.

The polypeptide of SEQ ID NO:4 includes five histidine triad residues, as follows:

amino acids 64-69; 188-193; 296-301; 541-546; and 625-630.

5

The polypeptide of SEQ ID NO:6 includes five histidine triad residues, as follows:

amino acids 63-68; 185-190; 289-294, 376-381; and 441-446.

10

In addition, the polypeptide of SEQ ID NO:4 includes two coiled-coil regions (amino acids 120-140 and amino acids 750-772) and the polypeptide of SEQ ID NO:6 includes one coiled-coil region (amino acids 119-152).

15

The polypeptide of SEQ ID NO: 8 includes the following regions:

HxxHxH: amino acids 63-68, 189-194, 309-314, 550-555, 634-639.

Coiled-coils: amino acids 118-145, 406-434, 462-493, 724-751.

20

In accordance with a further aspect of the invention, a vaccine of the type hereinabove described is administered for the purpose of preventing or treating infection caused by *S. pneumoniae*.

25

A vaccine, or vaccine composition, in accordance with the present invention may include one or more of the hereinabove described polypeptides or active fragments thereof. When employing more than one polypeptide or active fragment, such two or more polypeptides and/or active fragments may be used as a physical mixture or as a fusion of two or more polypeptides or active fragments. The fusion fragment or fusion polypeptide may be produced,

for example, by recombinant techniques or by the use of appropriate linkers for fusing previously prepared polypeptides or active fragments.

5 In an embodiment of the invention, there is provided (a) a polypeptide that is at least 95% identical or at least 97% identical or 100% identical to (i) a polypeptide sequence comprising amino acids 1 to 819 of SEQ ID NO:4 or (ii) a polypeptide sequence comprising amino acids 1-460 of SEQ ID NO:6; or (b) an active fragment of the polypeptide of (a).

10 In the case where the polypeptide is a variant of the polypeptide comprising the mature polypeptide of SEQ ID NO:4 or SEQ ID NO:6, or any of the active fragments of the invention, the variation in the polypeptide or fragment is generally in a portion thereof other than the histidine triad residues and the coiled-coil region, although variations in one or more of these regions  
15 may be made.

In many cases, the variation in the polypeptide or active fragment is a conservative amino acid substitution, although other substitutions are within the scope of the invention.

20

In accordance with the present invention, a polypeptide variant includes variants in which one or more amino acids are substituted and/or deleted and/or inserted.

25

In another aspect, the invention relates to passive immunity vaccines formulated from antibodies against a polypeptide or active fragment of a polypeptide of the present invention. Such passive immunity vaccines can be utilized to prevent and/or treat pneumococcal infections in patients. In this manner, according to a further aspect of the invention, a vaccine can be

produced from a synthetic or recombinant polypeptide of the present invention or an antibody against such polypeptide.

5 In still another aspect the present invention relates to a method of using one or more antibodies (monoclonal, polyclonal or sera) to the polypeptides of the invention as described above for the prophylaxis and/or treatment of diseases that are caused by pneumococcal bacteria. In particular, the invention relates to a method for the prophylaxis and/or treatment of infectious diseases that are caused by *S. pneumoniae*. In a still further preferred aspect,  
10 the invention relates to a method for the prophylaxis and/or treatment of otitis media, nasopharyngeal, bronchial infections, and the like in humans by utilizing a vaccine of the present invention.

Generally, vaccines are prepared as injectables, in the form of aqueous  
15 solutions or suspensions. Vaccines in an oil base are also well known such as for inhaling. Solid forms which are dissolved or suspended prior to use may also be formulated. Pharmaceutical carriers are generally added that are compatible with the active ingredients and acceptable for pharmaceutical use. Examples of such carriers include, but are not limited to, water, saline  
20 solutions, dextrose, or glycerol. Combinations of carriers may also be used.

Vaccine compositions may further incorporate additional substances to stabilize pH, or to function as adjuvants, wetting agents, or emulsifying agents, which can serve to improve the effectiveness of the vaccine.  
25

Vaccines are generally formulated for parental administration and are injected either subcutaneously or intramuscularly. Such vaccines can also be formulated as suppositories or for oral administration, using methods known in the art.

The amount of vaccine sufficient to confer immunity to pathogenic bacteria is determined by methods well known to those skilled in the art. This quantity will be determined based upon the characteristics of the vaccine recipient and the level of immunity required. Typically, the amount of vaccine to be administered will be determined based upon the judgment of a skilled physician. Where vaccines are administered by subcutaneous or intramuscular injection, a range of 50 to 500  $\mu$ g purified protein may be given.

10 The present invention is also directed to a vaccine in which a polypeptide or active fragment of the present invention is delivered or administered in the form of a polynucleotide encoding the polypeptide or active fragment, whereby the polypeptide or active fragment is produced *in vivo*. The polynucleotide may be included in a suitable expression vector and  
15 combined with a pharmaceutically acceptable carrier.

In addition, the polypeptides of the present invention can be used as immunogens to stimulate the production of antibodies for use in passive immunotherapy, for use as diagnostic reagents, and for use as reagents in  
20 other processes such as affinity chromatography.

In another aspect the present invention provides polynucleotides which encode the hereinabove described polypeptides and active fragments of the invention. The polynucleotide of the present invention may be in the form of  
25 RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand.

In accordance with another aspect of the present invention, there is

provided

(A) an isolated polynucleotide that is at least 90% identical to a polynucleotide sequence encoding (i) a polypeptide comprising amino acids 1-819 of SEQ ID NO:4 or (ii) a polypeptide comprising amino acids 1-460 of SEQ ID NO:6, or

(B) a fragment of the polynucleotide of (A) that encodes an active polypeptide fragment or

(C) a polynucleotide that is at least 90% identical to a polynucleotide sequence encoding an active fragment of (i) a polypeptide comprising amino acids 1 to 800 of SEQ ID NO:8 or (ii) a polypeptide comprising amino acids 1 to 800 of SEQ ID NO:10.

In specific embodiments, the polynucleotide is at least 95% identical, preferably at least 97% identical, and even 100% identical to such polynucleotide sequence.

The term "polynucleotide encoding a polypeptide" encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.

The present invention further relates to variants of polynucleotides. The variants of the polynucleotides may be a naturally occurring allelic variant of the polynucleotides or a non-naturally occurring variant of the polynucleotides. The variants include variants in which one or more bases are substituted, deleted or inserted. Complements to such coding polynucleotides may be utilized to isolate polynucleotides encoding the same or similar polypeptides. In particular, such procedures are useful to obtain native immunogenic portions of polypeptides from different serotypes of *S. pneumoniae*, which is especially

useful in the production of "chain" polypeptide vaccines containing multiple immunogenic segments.

5 SEQ ID NO:5 is a representative example of a polynucleotide encoding the polypeptide of SEQ ID NO:4 and SEQ ID NO:7 is a representative example of a polynucleotide encoding the polypeptide of SEQ ID NO:6. SEQ ID NO:9 is a representative example of a polynucleotide encoding the polypeptide of SEQ ID NO:8, and SEQ ID NO:11 is a representative example of a polynucleotide encoding the polypeptide of SEQ ID NO:10. As a result of the known  
10 degeneracy of the genetic code, other polynucleotides that encode the polypeptides of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 and SEQ ID NO:10 should be apparent to those skilled in the art from the teachings herein.

15 The polynucleotides encoding the immunogenic polypeptides described above may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptides of the present invention. The marker sequence may be, for example, a hexa-histidine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptides fused to the marker in the case of a bacterial host, or, for  
20 example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

25 The present invention also relates to vectors which include polynucleotides encoding one or more of the polypeptides of the invention, host cells which are genetically engineered with vectors of the invention and the production of such immunogenic polypeptides by recombinant techniques in an isolated and substantially immunogenically pure form.



Host cells are genetically engineered (transduced or transformed or transfected) with the vectors comprising a polynucleotide encoding a polypeptide of the invention. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the polynucleotides which encode such polypeptides. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

Vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the E. coli. lac or trp, the phage lambda P<sub>L</sub> promoter and other promoters known to control expression of genes in

prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

5

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

10

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the proteins.

15

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 and Spodoptera Sf9; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

20

More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter,

25

operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen, Inc.), pbs, pD10, phagescript, psiX174, 5 pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

10

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.

Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P<sub>R</sub>, P<sub>L</sub> and TRP. Eukaryotic 15 promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

20

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium 25 phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

The constructs in host cells can be used in a conventional manner to

produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

5           Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described  
10 by Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

          Transcription of the DNA encoding the polypeptides of the present  
15 invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples including the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the  
20 late side of the replication origin, and adenovirus enhancers.

          Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and  
25 a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK),  $\alpha$ -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with

translation initiation and termination sequences. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

5

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.

15

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

25

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

5

Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, a french press, mechanical disruption, or use of cell lysing agents, such methods are well know to those skilled in the art. However, preferred are host cells which  
10 secrete the polypeptide of the invention and permit recovery of the polypeptide from the culture media.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems  
15 include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites,  
20 polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

25 The polypeptides can be recovered and/or purified from recombinant cell cultures by well-known protein recovery and purification methods. Such methodology may include ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity

chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. In this respect, chaperones may be used in such a refolding procedure. Finally, high performance liquid chromatography (HPLC)  
5 can be employed for final purification steps.

The polypeptides that are useful as immunogens in the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or  
10 eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated.

15 Procedures for the isolation of the individually expressed polypeptides may be isolated by recombinant expression/isolation methods that are well-known in the art. Typical examples for such isolation may utilize an antibody to a conserved area of the protein or to a His tag or cleavable leader or tail that is expressed as part of the protein structure.

20 The polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single  
25 chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.

Antibodies generated against the polypeptides corresponding to a

sequence of the present invention can be obtained by direct injection of the polypeptides into an animal.

For preparation of monoclonal antibodies, any technique which provides  
5 antibodies produced by continuous cell line cultures can be used. Examples  
include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495-  
497), the trioma technique, the human B-cell hybridoma technique (Kozbor et  
al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to  
produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal  
10 Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

Techniques described for the production of single chain antibodies (U.S.  
Patent 4,946,778) can be adapted to produce single chain antibodies to  
immunogenic polypeptide products of this invention. Also, transgenic mice  
may be used to express humanized antibodies to immunogenic polypeptide  
15 products of this invention.

The invention will be further described with respect to the following  
examples; however, the scope of the invention is not limited thereby:

## 20 **Example 1**

### Active Protection with Anti-Sp36

#### *A. Cloning, expression, and purification of SP36*

25 The genomic DNA used as target for amplification was isolated from  
*S. pneumoniae* Norway strain (serotype 4), the same strain used for genomic  
sequencing. The complete sequence of the Sp36 gene (SEQ ID NO:9), and  
its predicted amino acid sequence (SEQ ID NO:8), are given in the Sequence  
Listing appended hereto. It was noted that the predicted amino acid



sequence included a hydrophobic leader sequence followed by a sequence (LSVC) similar to the consensus sequence for Type II signal peptidase (LxxC, in which both x's typically represent small amino acids). Primers (listed as SEQ ID NOS:1-3) were designed that would amplify the Sp36 gene and allow  
5 its cloning into pQE10 and expression as a histidine-tagged protein lacking the signal sequence for purification by nickel-affinity chromatography. Cloning of the fragment amplified by SEQ ID Nos 1 and 3 would result in a protein containing amino acids 2 through 800 of Sp36; cloning of the fragment amplified by SEQ ID Nos 2 and 3 would result in a protein  
10 containing amino acids 7 through 800 of Sp36 (amino acid numbers refer to SEQ ID NO:8).

#### *B. Active Protection With Sp36 Vaccination*

15 In each of the three experiments shown in Figures 1A-1C, C3H/HeJ mice (10/group) were immunized intraperitoneally (i.p.) with Sp36 protein (15 µg in 50 µl PBS emulsified in 50 µl complete Freund's adjuvant (CFA)). A group of 10 sham-immunized mice received PBS with adjuvant. A second immunization of 15 µg protein with incomplete Freund's adjuvant (IFA) was  
20 administered 4 weeks later; the sham group received PBS with IFA. Blood was drawn (retro-orbital bleed) at weeks 3, 6, and 9; and sera from each group were pooled for analysis of anti-Sp36 antibody by ELISA. Mice were challenged at week 10 by an i.p. injection of approximately 500 CFU *S. pneumoniae* strain SJ2 (serotype 6B; provided by P. Flynn, St. Jude  
25 Children's Research Hospital, Memphis, TN). In preliminary experiments, the LD<sub>50</sub> of this strain was determined to be approximately 10 CFU. Mice were monitored for 14 days for survival.

The three experiments shown in Figures 1A-1C used slightly different

preparations of recombinant Sp36. The experiments shown in Figure 1A and 1B both used Sp36 containing amino acids 20-815, but different batches of protein were used in the two experiments. The experiment shown in Figure 1C used Sp36 containing amino acids 25-815.

5

In the experiment shown in Figure 1A, 9-week sera collected from the ten mice immunized with Sp36 (first batch) had an endpoint ELISA titer of 1:4,096,000. No anti-Sp36 antibody was detected in sera from sham-immunized mice. One hundred percent of the mice immunized with Sp36  
10 protein survived the challenge (520 cfu of pneumococci) for 14 days. Eighty percent of sham-immunized mice were dead by day 4, and the remainder survived.

In the experiment shown in Figure 1B, 9-week sera collected from the  
15 ten mice immunized with Sp36 (second batch) had an endpoint ELISA titer of > 1:4,096,000. No anti-Sp36 antibody was detected in sera from sham-immunized mice. One hundred percent of the mice immunized with Sp36 protein survived the challenge (510 cfu of pneumococci) for 14 days. Of the sham-immunized mice, eighty percent were dead by day 4, and all died by  
20 day 9.

In the experiment shown in Figure 1C, 9-week sera collected from the ten mice immunized with Sp36 (containing amino acids 25- 815) had an endpoint ELISA titer of 1:4,096,000. No anti-Sp36 antibody was detected in  
25 sera from sham-immunized mice. One hundred percent of the mice immunized with Sp36 protein survived the challenge (510 cfu of pneumococci) for 14 days. Of the sham-immunized mice, ninety percent died by day 4, and all died by day 12. These data demonstrate that immunization of mice with recombinant Sp36 proteins elicits a response capable of

protecting against systemic pneumococcal infection and death. This protection was not strain-specific: the recombinant pneumococcal protein was cloned from a serotype 4 strain, while the challenge was with a heterologous strain, SJ2 (serotype 6B).

5

## Example 2

### Passive Protection with Anti-Sp36 Antisera

#### *A. Generation of Rabbit Immune Sera*

10

Following collection of preimmune serum, a New Zealand White rabbit was immunized with 250 µg of Sp36 (containing amino acids 20-815) in CFA. The rabbit was given two boosts of 125 µg Sp36 in IFA on days 29 and 50 and bled on days 39 and 60. A second rabbit was immunized with a control antigen, *E. coli* FimC.

15

#### *B. Passive Protection in Mice*

C3H/HeJ mice (10 mice/group) were passively immunized by two i.p. injections of 100 µl of rabbit serum. The first injection was administered twenty-four hours before challenge with 172 cfu of *S. pneumoniae* strain SJ2, and the second injection was given four hours after challenge. Figure 2 shows the survival of mice after infection with two different strains of pneumococci.

25

Figure 2A shows that of mice injected with 172 cfu of strain SJ2 (Figure 2A), one hundred percent of the mice immunized with rabbit immune serum raised against Sp36 protein survived the 21-day observation period. Of the mice immunized with the control serum (anti-FimC), eighty percent

died by day 8, and ninety percent died by day 12. Figure 2B shows that of mice injected with 862 cfu of strain EF6796, ninety percent of the mice immunized with rabbit immune serum raised against Sp36 protein survived the 8-day observation period. Of those given a control serum (collected from a rabbit before immunization), ninety percent died by day 8.

These data indicate that the protection against pneumococcal infection resulting from immunization with Sp36 is antibody-mediated, since mice can be protected by passive transfer of serum from a hyperimmunized rabbit. As seen in the mouse active challenge experiments described above, serum directed against recombinant Sp36 protein cloned from a serotype 4 strain was protective against challenge with heterologous strains.

### Example 3

#### Conservation of Sp36 Among Strains of *S. pneumoniae*

##### A. Western blotting

The 23 pneumococcal strains used in this experiment were obtained from the American Type Culture Collection (Rockville, MD) and include one isolate each of the 23 serotypes in the multivalent pneumococcal vaccine. For total cell lysates, pneumococci were grown to mid-logarithmic phase (optical density at 620 nm, 0.4 to 0.6) in 2 ml Todd-Hewitt broth with 0.5% yeast extract (Difco, Detroit, ME) at 37°C. Bacteria were harvested by centrifugation and washed twice with water. Pellets were resuspended in 200 µl lysis buffer (0.01% sodium dodecyl sulfate, 0.15 M sodium citrate and 0.1% sodium deoxycholate) and incubated at 37°C for 30 min, then diluted in an equal volume 2x SSC (0.3 M sodium chloride, 0.03 M sodium citrate). Lysates were separated by SDS-PAGE, transferred to nitrocellulose

membranes (Bio-Rad Laboratories, Hercules, CA), and probed with antibody in a standard Western blotting procedure. Sera from ten C3H/HeJ mice immunized with Sp36 (as described in Example 1) were pooled and used at a dilution of 1:3000. Bound antibody was detected with peroxidase-  
5 conjugated sheep anti- mouse IgG using the chemiluminescence kit from Amersham, Inc. (Cambridge, MA).

The mouse anti-Sp36 sera detected two major bands with apparent molecular weights of 97 and 100 kDa in all 23 pneumococcal lysates tested  
10 (shown in Figure 3). The Sp36 signals obtained from *S. pneumoniae* serotypes 1, 5, 17F and 22F were lower, indicating either that the level of Sp36 expression is reduced in these strains, or that Sp36 in these strains is antigenically different.

15 These data show that Sp36 is antigenically conserved among strains of the 23 pneumococcal serotypes represented in the current polysaccharide vaccine.

## 20 *B. Southern blotting*

Genomic DNA was prepared from each of the 23 pneumococcal strains listed in the previous section and also from strain SJ2. DNA was digested with *PvuII* and *BamHI*, electrophoresed in an agarose gel and  
25 transferred to a nylon membrane. A probe was prepared by amplifying the Sp36 gene from Norway type 4 DNA (as in Example 1) and labeling the amplified fragment with fluorescein by the random-priming method, using a kit from Amersham. Hybridization, washing, and exposure of film were carried out as in the protocol supplied by Amersham. Figure 4 shows that

the Sp36 probe hybridized with DNA from each of the 24 strains studied. The lane marked "M" contained DNA from lambda phage, digested with *HindIII* and labeled with fluorescein, as molecular weight markers.

#### 5    **Example 4**

##### Immunogenicity of Sp36 in Humans

In order to determine whether Sp36 is immunogenic during human pneumococcal infection, sera from patients with culture-proven  
10    pneumococcal bacteremia were used in Western blots containing recombinant Sp36 protein. In the experiment shown in Figure 5, sera from five patients (indicated as 1 through 5) were diluted 1:3000 and used to probe blots containing full-length Sp36, the N-terminal half of Sp36 (preceding the proline-rich region), or the C-terminal half of Sp36 (following  
15    the proline-rich region). Lanes labeled A (acute) were probed with serum collected shortly after diagnosis of pneumococcal infection; lanes C (convalescent) were probed with serum collected either one month later (patients 1, 2, and 3) or eight days after the first serum collection (patients 4 and 5). For patients 2, 3 and 5, reactivity of the convalescent serum with  
20    Sp36 was stronger than that of the corresponding acute serum. The difference between the acute and convalescent sera was particularly evident for reactivity with the C-terminal half of the protein.

In additional experiments (not shown), convalescent sera from 23  
25    patients with pneumococcal infections were tested individually for reactivity with full-length Sp36: 20 of the 23 sera were found to bind Sp36 on a Western blot.

These experiments indicate that Sp36 is recognized by the human

immune system and suggest that antibodies able to bind the Sp36 protein may be produced during natural *S. pneumoniae* infection in humans. Since the patients were infected with a variety of pneumococcal strains, these data also support the idea that Sp36 is antigenically conserved.

5

#### Example 5

Table 1 provides the percent identity between the various sequences.

10 Alignment of the predicted amino acid sequences of PhtA, PhtB, PhtD, and PhtE using the MEGALIGN program of Lasergene showed strong N-terminal homology with substantial divergence of the C-termini (Figure 6). The alignment of the nucleotide sequences of the same genes is shown in Figure 7. Amino acid and nucleotide sequences were compared using the  
15 identity weighting in a Lipman-Pearson pairwise alignment, in which the number of matching residues is divided by the total of matching residues plus the number of mismatched residues plus the number of residues in gaps. In the table below, the percent identity between each pair of sequences is shown at the intersection of the corresponding row and column.

20

#### Example 6

##### Active Protection with PhtD Vaccination.

Mice immunized with recombinant PhtD derived from strain N4 generated potent antibody titers (reciprocal endpoint titers ranging from  
25 2,048,00 to 4,096,000). Mice immunized with PhtD were protected against death following intraperitoneal injection with either of three heterologous strains, SJ2 (serotype 6B; provided by P. Flynn, St. Jude Children's Research

Hospital, Memphis, TN), EF6796 (serotype 6A) or EF5668 (serotype 4; both strains provided by D. Briles, University of Alabama, Birmingham). In the experiment shown in Figure 8 (Panel A), all ten of the sham-immunized mice died within 10-days after challenge with virulent pneumococci (strain SJ2), while eighty percent of the PhtD-immunized mice survived the 15-day observation period. Immunization with PhtD also protected against a serotype 6A strain, EF6796 (Panel B) and a serotype 4 strain, EF5668 (Panel C). In the experiment shown in Figure 8 (Panel B), all ten of the sham-immunized mice died within 7-days after challenge with virulent pneumococci (strain EF6796), while ninety percent of the PhtD-immunized mice survived the 15-day observation period. In the experiment shown in Figure 8 (Panel C), all ten of the sham-immunized mice died within 6-days after challenge with virulent pneumococci (strain EF5668), while eight of nine mice immunized with PhtD survived the 15-day observation period.

15

20



Table 1. Percent Identities

Percent Identity Between Amino Acid Sequences				
	PhtA	PhtB	PhtD	PhtE
PhtA	---	66.4	63.9	49.5
PhtB		---	87.2	49.5
PhtD			---	49.8
PhtE				---
Percent Identity Between Nucleotide Sequences				
	PhtA	PhtB	PhtD	PhtE
PhtA	---	58.3	59.3	47.9
PhtB		---	86.4	47.4
PhtD			---	47.9
PhtE				---

WHAT IS CLAIMED IS:

1. A vaccine composition comprising:

- (a) at least one member selected from the groups consisting  
5 of (i) a polypeptide comprising a polypeptide sequence that is at least 90% identical to amino acids 1-819 of SEQ ID NO:4; (ii) a polypeptide comprising a polypeptide sequence that is at least 90% identical to amino acids 1-460 of SEQ ID NO:6; (iii) a fragment of the polypeptide of (i) that includes at least one of a histidine triad residue or coiled-coil region; (iv) a fragment of the  
10 polypeptide of (ii) that includes at least one of a histidine triad residue or a coiled-coil region; (v) a fragment of a polypeptide that is at least 90% identical to the polypeptide sequence comprising amino acids 1-800 of SEQ ID NO:8, wherein said fragment includes at least one of a histidine triad residue or coiled-coil region wherein said fragment includes at least 80 amino  
15 acids and no more than 680 amino acids; and (vi) a fragment of a polypeptide that is at least 90% identical to the polypeptide sequence comprising amino acids 1-800 of SEQ ID NO:10, wherein said fragment includes at least one of a histidine triad residue or coiled-coil region wherein said fragment includes at least 80 amino acids and no more than 680 amino  
20 acids; and
- (b) a pharmaceutically acceptable carrier.

2. A process for preventing infection caused by *S. pneumoniae* comprising:

- 25 administering the vaccine of claim 1.


3. A vaccine composition comprising:

- (a) at least one antibody against a member selected from the group consisting of (i) a polypeptide comprising a polypeptide sequence that

is at least 90% identical to amino acids 1-819 of SEQ ID NO:4; (ii) a polypeptide comprising a polypeptide sequence that is at least 90% identical to amino acids 1-460 of SEQ ID NO:6; (iii) a fragment of the polypeptide of (i) that includes at least one of histidine triad residue or coiled-coil region; (iv) 5 a fragment of the polypeptide of (ii) that includes at least one of a histidine triad residue or a coiled-coil region; (v) a fragment of a polypeptide that is at least 90% identical to the polypeptide sequence comprising amino acids 1-800 of SEQ ID NO:8, wherein said fragment includes at least one of a histidine triad residue or coiled-coil region wherein said fragment includes at 10 least 80 amino acids and no more than 680 amino acids and (vi) a fragment of a polypeptide that is at least 90% identical to the polypeptide sequence comprising amino acids 1-800 of SEQ ID NO:10, wherein said fragment includes at least one of a histidine triad residue or coiled-coil region wherein said fragment includes at least 80 amino acids and no more than 680 amino 15 acids.

20

25

**Figure 1**



**Figure 2****A. Strain SJ2 (serotype 6B)****B. Strain EF6796 (serotype 6A)**

FIG. 3A




FIG. 3B




FIG. 4






FIG. 5A




PhtA

FIG. 5B



PhtA N-terminal

FIG. 5C



PhtA C-terminal



Figure 6 (a)

CSYELGRHQAGQKKESNRVS YIDGDDOAGQKAENLT PDEVSKREGINAEO Majority

10 20 30 40 50

1 CSYELGRHQAGQ VKKESNRVS YIDGDDOAGQKAENLT PDEVSKREGINAEO PhtD.PRO  
1 CSYELGRYQAGQDKKESNRVAYIDGDDOAGQKAENLT PDEVSKREGINAEO PhtB.pro  
1 CSYELGLYQA-RTVKENNRRVS YIDGKQATQKTENLT PDEVSKREGINAEO PhtA.PRO  
1 CAYALNQHRS-QENKDNRRVS YVDGSSQKSENLT PDDQVSSQRREGIQAEQ PhtE.PRO

IVIKITDQGYVTSHGDDHYHYNGKVYPYDAIISEELLMKDPNYQLKDS DIV Majority

60 70 80 90 100

51 IVIKITDQGYVTSHGDDHYHYNGKVYPYDAIISEELLMKDPNYQLKDS DIV PhtD.PRO  
51 IVIKITDQGYVTSHGDDHYHYNGKVYPYDAIISEELLMKDPNYQLKDS DIV PhtB.pro  
50 IVIKITDQGYVTSHGDDHYHYNGKVYPYDAIISEELLMKDPNYQLKDS DIV PhtA.PRO  
50 IVIKITDQGYVTSHGDDHYHYNGKVYPYDALPSEELLMKDPNYQLKDS DIV PhtE.PRO

NEVKGGYVIKVDGKYYVYLKDAAHADNVRTKEEINRQKQEHSHNHGEG-- Majority

110 120 130 140 150

101 NEIKGGYVIKVDGKYYVYLKDAAHADNIRTKKEIKRQKQEHSHNHGG-- PhtD.PRO  
101 NEIKGGYVIKVMNGKYYVYLKDAAHADNIRTKKEIKRQKQERSHNHNS-- PhtB.pro  
100 NEVKGGYVIKVDGKYYVYLKDAAHADNVRTKEEINRQKQEHSSQHRREGGTP PhtA.PRO  
100 NEVKGGYIKVDGKYYVYLKDAAHADNVRTKDEINRQKQEHVVKDNE-- PhtE.PRO

RNDXAVAAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKN Majority

160 170 180 190 200

149 SINDQAVVAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKN PhtD.PRO  
148 RADNAAVAAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKN PhtB.pro  
150 RNDGAVALLARSQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKN PhtA.PRO  
146 KVNNSNVAVARSQGRYTTNDGYVVPFNPAIDIIEDTGNAIIVPHGGHYHYIPKS PhtE.PRO

ELSASELAAAEAYLNGK-----OQSRPSSSSSYNANPAQPRLSE Majority

210 220 230 240 250

199 ELSASELAAAEAYWNGK-----OQSRPSSSSSYNANPAQPRLSE PhtD.PRO  
198 ELSASELAAAEAYWNGK-----OQSRPSSSSSYNANPAQPRLSE PhtB.pro  
200 ELSASELAAAEAFLSGRGNLSNSRTYRRQNSDNTSRTNWPVPSVSNPGTTN PhtA.PRO  
196 DLSASELAAAKAHLAOK-----NMQPSQLSYSSSTASD--NN PhtE.PRO

THNLTVTPTYHOANOGENISSLLKELYAKPLSERHVESDGLVFPDPAQITS Majority

260 270 280 290 300

238 NHNLTVTPTYHQ-NQGENISSLLRELYAKPLSERHVESDGLIFDPAQITS PhtD.PRO  
237 NHNLTVTPTYHQ-NQGENISSLLRELYAKPLSERHVESDGLIFDPAQITS PhtB.pro  
250 TNTSNNNSNTNSQASQSDNDIDSLKQLYKLPFSQRHVESDGLVFPDPAQITS PhtA.PRO  
230 TQSVAKGSTSKFANKSENLSLLEKELYDSPSAQRYSSES DGLVFPDAKILIS PhtE.PRO

RTARGVAVPHGDHYHFIPYSOMSELEERARIIPLYRSNHVVPDSRPEQ Majority

310 320 330 340 350

287 RTARGVAVPHGNHYHFIPYEQMSELEKRIARIIPLYRSNHVVPDSRPEQ PhtD.PRO  
286 RTARGVAVPHGNHYHFIPYEQMSELEKRIARIIPLYRSNHVVPDSRPEE PhtB.pro  
300 RTARGVAVPHGDHYHFIPYSOMSELEERARIIPLYRSNHVVPDSRPEQ PhtA.PRO  
280 RTPNGVAIPHGDHYHFIPYSKLSELEKRIARIMVPI-----PhtE.PRO

**Figure 6 (b)**

[illegible]

	X Q X D X N X X X X E E X	- - P E - - - - -	P - - - - -		Majority
	710	720	730	740	750
687	D Q D S K P D E D K E H D E V S E P T H P E S D E K E N H A G L N P S A D N L Y K P S T D T E E T E				PhtD.PRO
680	G R A D T N O T E K P S E E K P O T E K P E E T - - - - -				PhtB.pro
696	H S E D F N K N F K A D E E P - - - - -				PhtA.PRO
449	- - - - -				PhtE.PRO
	E E X E E T P X E X E X P O V E T E K V E A K L X E A E X L L X K V T D P S I K X N A X E T L T G L				Majority
	760	770	780	790	800
737	E E A E D T T D E A E I P Q V E N S V I N A K I A D A E A L L E K V T D P S I R Q N A M E T L T G L				PhtD.PRO
722	E E P E E S P E S E E P Q V E T E K V E A Q L K E A E V L L A K V T D S S L K A N A T E T L A G L				PhtB.pro
711	- - - V E E T P A E P E V P Q V E T E K V E A Q L K E A E V L L A K V T D S S L K A N A T E T L A G L				PhtA.PRO
449	- - - - - F K K D L T E E Q I - - - - -				PhtE.PRO
	K N N L L G T X D N N T I M A B A E K L L A L L K E S X P X X X - - - K - - K - -				Majority
	810	820	830	840	
787	K S S L L L G T K D N N T I S A E V D S L L A L L K E S Q P A P I				PhtD.PRO
772	K N N L L F G T Q D N N T I M A B A E K L L A L L K E S K				PhtB.pro
759	R N N L T L Q I M D N N S I M A B A E K L L A L L K G S N P S S V S K E K I N K L N				PhtA.PRO
459	- - - - -				PhtE.PRO

**Decoration 'Decoration #2':** Box residues that match the Consensus exactly.

Figure 7(a)

TCCTATGAGCTTGGAGTTTATCAAGCTGGTCAGGCTTAAGAAAGAGTCTAA Majority  
10 20 30 40 50

61 TCTTACGAGTTTGGGACTGTATCAAGCTAGAACGGTTAAGGAAAA--TAA phcA.SEQ  
1 TCCTATGAGCTTGGACGTTACCAAGCTGGTCAGGATAAGAAAGAGTCTAA phcB.seq  
1 TCCTATGAACCTTGGTCGTCACCAAGCTGGTCAGGTTAAGAAAGAGTCTAA phcD.SEQ  
64 GCCTATGCACTAAACCAGCATC--GTTCG-CAGGAAAAATAAGGACAAATAA phcE.SEQ

TCGTGTTTCTTATATAGATGGTGATCAGGCTGGTCAAAAGGCAGAAAACT Majority  
60 70 80 90 100

108 TCGTGTTTCTTATATAGATGGGAAAAACAAGCGACGCAAAAAACGGAGAAATT phcA.SEQ  
51 TCGAGTTTGCTTATATAGATGGTGATCAGGCTGGTCAAAAGGCAGAAAACT phcB.seq  
51 TCGAGTTTCTTATATAGATGGTGATCAGGCTGGTCAAAAGGCAGAAAACT phcD.SEQ  
111 TCGTGTTCTCTTATGTGGATGGCAGCCAGTCAAGTCAGAAAAAGTGAAAACT phcE.SEQ

TGACACCAGATGAGGTTAGTAAGAGGGAGGGGATCAACGCTGAGCAAAAT Majority  
110 120 130 140 150

158 TGACTCCTGATGAGGTTAGCAAGCGTGAAAGGAATCAATGCTGAGCAAAATC phcA.SEQ  
101 TGACACCAGATGAAGTCAAGTAAGAGGGAGGGGATCAACGCCGAAACAAATC phcB.seq  
101 TGACACCAGATGAAGTCAAGTAAGAGGGAGGGGATCAACGCCGAAACAAATC phcD.SEQ  
161 TGACACCAGACCAAGGTTAGCCAGAAAGAAAGGAATTCAGGCTGAGCAAAATC phcE.SEQ

GTCATCAAGATTACGGATCAAGGTTATGTGACCTCTCATGGAGACCATTAA Majority  
160 170 180 190 200

208 GTCATCAAGATAAACAGACCAAGGCTATGTCACTTCACATGGCGACCACTA phcA.SEQ  
151 GTTATCAAGATTACGGATCAAGGTTATGTGACCTCTCATGGAGACCATTAA phcB.seq  
151 GTCATCAAGATTACGGATCAAGGTTATGTGACCTCTCATGGAGACCATTAA phcD.SEQ  
211 GTAATCAAAATTAACAGATCAGGGGCTATGTAACGTACACAGGCTGACCACTA phcE.SEQ

TCATTACTATAAATGGCAAGGTTTCTTATGATGCCATCATCAGTGAAGAGC Majority  
210 220 230 240 250

258 TCATTATTACAATGGTAAGGTTTCTTATGACGCTATCATCAGTGAAGAAAT phcA.SEQ  
201 TCATTACTATAAATGGCAAGGTTTCTTATGATGCCATCATCAAGTGAAGAGC phcB.seq  
201 TCATTACTATAAATGGCAAGGTTTCTTATGATGCCATCATCAGTGAAGAGC phcD.SEQ  
261 TCATTACTATAAATGGGAAAGTTTCTTATGATGCCCTCTTTAGTGAAGAAC phcE.SEQ

TCCTCATGAAAGATCCGAAATTATCAAGTTGAAGGATTCAAGATATTGTCAAT Majority  
260 270 280 290 300

308 TACTCATGAAAGATCCAAACTATAAGCTAAAAAGATGAGGATATTGTTAAT phcA.SEQ  
251 TCCTCATGAAAGATCCGAAATTATCAAGTTGAAGGATTCAAGACATTGTCAAT phcB.seq  
251 TCCTCATGAAAGATCCGAAATTATCAAGTTGAAGGATTCAAGACATTGTCAAT phcD.SEQ  
311 TCTTGATGAAAGGATCCAAACTATCAACTTAAAGACGCTGATATTGTCAAT phcE.SEQ

GAAAGTCAAGGGTGGTTATGTTATCAAGGTAGATGGAAAAATACTATGTTTA Majority  
310 320 330 340 350

358 GAGGTCAAGGGTGGATATGTTATCAAGGTAGATGGAAAAATACTATGTTTA phcA.SEQ  
301 GAAATCAAGGGTGGTTATGTCATTAAAGGTAAACGGTAAATACTATGTTTA phcB.seq  
301 GAAATCAAGGGTGGTTATGTTATCAAGGTAGATGGAAAAATACTATGTTTA phcD.SEQ  
361 GAAGTCAAGGGTGGTTATATCATCAAGGTGATGGAAAAATAATTATGTCTA phcE.SEQ

Figure 7(b)

CCTTAAGGATGCAGC CATGCGGATAATGTTTCGGACAAAAGAGAGATTAA Majority  
360 370 380 390 400  
408 CCTTAAGGATGCTGCCACGCGGATAACGTCCGTACAAAAGAGGAAATCA phtA.SEQ  
351 CCTTAAGGATGCRGCTCATGCGGATAAATATTCGGACAAAAGAGAGATTAA phtB.seq  
351 CCTTAAGGATGCAGCTCATGCGGATAAATATTCGGACAAAAGAGAGATTAA phtD.SEQ  
411 CCTGAAAGATGCAGCTCATGCTGATAAATGTTTCGAACTAAAGATGAAATCA phtE.SEQ

ATCGTCAGAAAGCAGGAACATAGTCATAATCATGAGGGTGGAXCT - - - A - - Majority  
410 420 430 440 450  
458 ATCGACAAAAACAAGAGCATAGTCAACATCGTGAAGGTGGAACTCCAAGA phtA.SEQ  
401 AACGTCAGAAAGCAGGAACGCAGTCATAAATCATAACTCAAGAGCA - - - - - phtB.seq  
401 AACGTCAGAAAGCAGGAACACAGTCATAAATCACGGGGGTGGTTCT - - - - - phtD.SEQ  
461 ATCGTCAAAAACAAGAACATGTCAAAGATAATGAG - - - - - AAAG phtE.SEQ

GATGATXXTGCTGTTGCTGTAGCCAGATCCCAAAGGACGCTATACAAACGGA Majority  
460 470 480 490 500  
508 AACGATGGTGCTGTTGCTGTGCTTGGCACGTTTCGCAAGGACGCTATACTACAGA phtA.SEQ  
445 GATAAT - - - GCTGTTGCTGTCAGCCAGAGCCCAAAGGACGTTATACAAACGGA phtB.seq  
445 AACGATCAAGCAGTAGTTGTCAGCCAGAGCCCAAAGGACGCTATACAAACGGA phtD.SEQ  
499 GTTAACTCTAATGTTGCTGTAGCAAAGGTCCTCAGGACGATATACGACAAA phtE.SEQ

TGATGGTTATATCTTTAATGCATCTGATATCATTTGAGGATACGGGTGATG Majority  
510 520 530 540 550  
558 TGATGGTTATATCTTTAATGCTTCTGATATCATAGAGGATACTGGTGATG phtA.SEQ  
492 TGATGGTTATATCTTCAATGCATCTGATATCATTTGAGGACACGGGTGATG phtB.seq  
495 TGATGGTTATATCTTCAATGCATCTGATATCATTTGAGGACACGGGTGATG phtD.SEQ  
549 TGATGGTTATGTCCTTTAATCCAGCTGATATTTATCGAAGATACGGGTAAATG phtE.SEQ

CTTATATCGTTTCCTCATGGGAGATCATTACCATTACATTCCTAAGAAATGAG Majority  
560 570 580 590 600  
608 CTTATATCGTTTCCTCATGGGAGATCATTACCATTACATTCCTAAGAAATGAG phtA.SEQ  
542 CTTATATCGTTTCCTCACGGCGGACCATTACCATTACATTCCTAAGAAATGAG phtB.seq  
545 CTTATATCGTTTCCTCACGGCGGACCATTACCATTACATTCCTAAGAAATGAG phtD.SEQ  
599 CTTATATCGTTTCCTCATGGAGGTCACTATCACTACATTCCTCAAAAGCGAT phtE.SEQ

TTATCAGCTAGCGAGTTAGCTGCTGCGAGAAAGCC - - - - TATTTGGATGGGA Majority  
610 620 630 640 650  
658 TTATCAGCTAGCGAGTTAGCTGCTGCGAGAAAGCCCTTCCTATCTGGTTCGAGG phtA.SEQ  
592 TTATCAGCTAGCGAGTTAGCTGCTGCGAGAAAGCC - - - - TATTTGGAATGGGA phtB.seq  
595 TTATCAGCTAGCGAGTTAGCTGCTGCGAGAAAGCC - - - - TATTTGGAATGGGA phtD.SEQ  
649 TTATCTGCTAGTGAATTAGCAGCAGCTAAAGCAC - - - - ATCTGGCTGGAA phtE.SEQ

AG - - - - - CAAAT - - - - GGGATCTCGTCCTTCTTCAAGTTCTAGTTATACTT Majority  
660 670 680 690 700  
708 AAATCTGTCAAATTTCAAAGAACCTATCGCCGACAAAATAGCGATAACACTT phtA.SEQ  
638 AG - - - - - CA - - - - - GGGATCTCGTCCTTCTTCAAGTTCTAGTTATAATG phtB.seq  
641 AG - - - - - CA - - - - - GGGATCTCGTCCTTCTTCAAGTTCTAGTTATAATG phtD.SEQ  
695 A - - - - - AAATATGCAACCGAGTC - - - - - AGTTA - AGCTATTCTT phtE.SEQ

Figure 7(c)

CAA-ATCCAGCTCAGTACCA-----AGATTGTCAGAGAACCACAAAT--CT Majority  
710 720 730 740 750

758 CAAGAACAAACTGGGTACCTTCTGTAAAGCAATCCAGGAAC TACAAATACT phtA.SEQ  
677 CAA-ATCCAGCTCA--ACCA-----AGATTGTCAGAGAACCACAAAT--CT phtB.seq  
680 CAA-ATCCAGCTCA--ACCA-----AGATTGTCAGAGAACCACAAAT--CT phtD.SEQ  
728 CAA-----CAGCT-AGT-----GACAAAT--AACA--CGCAATCTGT phtE.SEQ

GACA-AAGCTGTCACTCCAACATTATCA-TCAAGCAAAATCAAGGTGAAAA Majority  
760 770 780 790 800

808 AACACAAGCAACCAACAGCAACACTAACAGTCAAGCAAGTCAAAAGTAATGA phtA.SEQ  
717 GA-----CTGTCACTCCAAC-TTATCA-TCAA-----AATCAAGGGGAAAAA phtB.seq  
720 GA-----CTGTCACTCCAAC-TTATCA-TCAA-----AATCAAGGGGAAAAA phtD.SEQ  
759 AGCAAAAG-GATCA-----ACTAGCAAGCCAGCAAAATAAATCTGAAAAA phtE.SEQ

CATTTCAAGTCTTTTGGGTGAATTGTATGCTAAACCTTTATCAGAACGCC Majority  
810 820 830 840 850

858 CATTTGATAGTCTCTTTGAAACAGCTCTACAAACTGCCCTTTGAGTCAACGAC phtA.SEQ  
756 CATTTCAAGCCTTTTACGTGAATTGTATGCTAAACCTTTATCAGAACGCC phtB.seq  
759 CATTTCAAGCCTTTTACGTGAATTGTATGCTAAACCTTTATCAGAACGCC phtD.SEQ  
801 TCTCCAGAGTCTTTTGAAGGAACCTCTATGATTACCTAGCGCCCAACGTT phtE.SEQ

ATGTGGAATCTGATGGCCTTTGTTTTTGACCCAGCGCAAAATCACAAAGTCGA Majority  
860 870 880 890 900

908 ATGTAGAAATCTGATGGCCTTTGTCTTTGATCCAGCACAAATCACAAAGTCGA phtA.SEQ  
806 ATGTGGAATCTGATGGCCTTTATTTTTCGACCCAGCGCAAAATCACAAAGTCGA phtB.seq  
809 ATGTGGAATCTGATGGCCTTTATTTTTCGACCCAGCGCAAAATCACAAAGTCGA phtD.SEQ  
851 ACAGTGAAATCAGATGGCCTTGGTCTTTTGACCCCTGCTAAGATTATCAGTCGT phtE.SEQ

ACCGCCAGAGGTGTTGCTGTCCCTCATGGTGACCATTAACCACTTTATCCC Majority  
910 920 930 940 950

958 ACAGCTAGAGGTGTTGCAAGTGCCACACGGAGATCATTACCACTTTATCCC phtA.SEQ  
856 ACCGCCAGAGGTGTAGCTGTCCCTCATGGTAACCATTAACCACTTTATCCC phtB.seq  
859 ACCGCCAGAGGTGTAGCTGTCCCTCATGGTAACCATTAACCACTTTATCCC phtD.SEQ  
901 ACACCAAAATGGAAGTTGCGATTCCGCGACCATTAACCACTTTATTCC phtE.SEQ

TTATGAACAAATGTCTGAATTGGAAAGAACGAATTGCTCGTATTATTCCCC Majority  
960 970 980 990 1000

1008 TTA CTCTCAAATGTCTGAATTGGAAAGAACGAATCGCTCGTATTATTATTTCCCC phtA.SEQ  
906 TTATGAACAAATGTCTGAATTGGAAAAAACGAATTGCTCGTATTATTATTTCCCC phtB.seq  
909 TTATGAACAAATGTCTGAATTGGAAAAAACGAATTGCTCGTATTATTATTTCCCC phtD.SEQ  
951 TTACAGCAAGCTTTCTGCCCTTAGAAAGAAAAGATTGCCAGAAAT----- phtE.SEQ

TTCGTTATCGTTCAAACCATTTGGGTACCAGATTCAAGACCAGAAAGAACCA Majority  
1010 1020 1030 1040 1050

1058 TTCGTTATCGTTCAAACCATTTGGGTACCAGATTCAAGGCCAGAAACAAACCA phtA.SEO  
956 TTCGTTATCGTTCAAACCATTTGGGTACCAGATTCAAGACCAGAAAGAACCA phtB.seo  
959 TTCGTTATCGTTCAAACCATTTGGGTACCAGATTCAAGACCAGAAACAAACCA phtD.SEO  
993 -----GGTGCC-----T-----ATCAGTGGAACTG phtE.SEO

Figure 7(d)

AGTCCACAATCGACTCCGGAAACCTAGTCCAAGTCCGCAACCTGCACCAAAA Majority  
1060 1070 1080 1090 1100

1108 AGTCCACAACCGACTCCGGAAACCTAGTCCAGGCCCGCAACCTGCACCAAAA phtA.SEQ  
1006 AGTCCACAACCGACTCCAGAAACCTAGTCCAAGTCCGCAACC - - - - - phtB.seq  
1009 AGTCCACAATCGACTCCGGAAACCTAGTCCAAGTCCGCAACCTGCACCAAAA phtD.SEQ  
1013 GTTCTACAGTT - - - - - TCTA - - - CAAA - - - - - TGCA - - - AAA phtE.SEQ

TC - T - AA - - AGCTCCAAGCAATCCAATTGATG - GAAATTGGTCAAAGAAG Majority  
1110 1120 1130 1140 1150

1158 TCTTAAATAAGACTCAA - - - ATTCTTCT - - - - - TTGGTTAGTCAGC phtA.SEQ  
1047 - - - - - AGCTCCAAGCAATCCAATTGATGGGAAATTGGTCAAAGAAG phtB.seq  
1059 TCCTCAAACAGCTCCAAGCAATCCAATTGATGGGAAATTGGTCAAAGAAG phtD.SEQ  
1039 CC - - - - - TAAATG - - - - - - - - - - - - - - - phtE.SEQ

CTGTTCCGAAAAGTAGGCCGATGGTTATGTCCTTTGAGGAGAAATGGAGTTTCT Majority  
1160 1170 1180 1190 1200

1196 TGGTACGAAAAGTTGGGGAAGGATATGTATTCGAAAGAAAAGGGCATCTCT phtA.SEQ  
1088 CTGTTCCGAAAAGTAGGCCGATGGTTATGTCTTTGAGGAGAAATGGAGTTTCT phtB.seq  
1109 CTGTTCCGAAAAGTAGGCCGATGGTTATGTCTTTGAGGAGAAATGGAGTTTCT phtD.SEQ  
1046 - - - - - AAGTAG - - - - - TGTCT - - - - - - - - - - - AGTCT - - - phtE.SEQ

CGTTATATCCCAGCCAAAGGATCTTTTCAGCAGAAACAGCAGCAGGCATTGA Majority  
1210 1220 1230 1240 1250

1246 CGTTATATCTTTGCGAAAAGATTTACCATCTGAAACTGTTAAAAAATCTTGA phtA.SEQ  
1138 CGTTATATCCCAGCCAAAGGATCTTTTCAGCAGAAACAGCAGCAGGCATTGA phtB.seq  
1159 CGTTATATCCCAGCCAAAGGATCTTTTCAGCAGAAACAGCAGCAGGCATTGA phtD.SEQ  
1062 - phtE.SEQ

TAGCAAACTGGCCAAAGCAGGAAAGTTTTTCTCATAAAGCTAGGAGCTAAGA Majority  
1260 1270 1280 1290 1300

1296 AAGCAAGTTATCAAAAACAAGAGAGTGTTTTACACACACTTTAACTGCTAAAAA phtA.SEQ  
1188 TAGCAAACTGGCCAAAGCAGGAAAGTTTTATCTCATAAAGCTAGGAACTAAGA phtB.seq  
1209 TAGCAAACTGGCCAAAGCAGGAAAGTTTTATCTCATAAAGCTAGGAGCTAAGA phtD.SEQ  
1066 - phtE.SEQ

AAACTGATCTTTCCTTCTAGTGATCGAGAAATTTTACGATAAAGGCTTATGAC Majority  
1310 1320 1330 1340 1350

1346 AAGAAAAATGTTGCTCCTCGTGACCAAGAAATTTTATGATAAAGCATATAAT phtA.SEQ  
1238 AAACTGACCTCCCATCTAGTGATCGAGAAATTTTACAAATAAGGCTTATGAC phtB.seq  
1259 AAACTGACCTCCCATCTAGTGATCGAGAAATTTTACAAATAAGGCTTATGAC phtD.SEQ  
1074 - AAGCAATCCTTCTTCT - - - - - - - - - - - TTAACGACAAG - - - - - phtE.SEQ

TTACTAGCAAGAATTCAACCAAGATTTACTTGATAATAAGGGTCGACAAGT Majority  
1360 1370 1380 1390 1400

1396 CTGTTAACTGAGGCTCATAAAGCCTTGTGTTGNAATAAAGGGTCGTAATTC phtA.SEQ  
1288 TTACTAGCAAGAATTCAACCAAGATTTACTTGATAATAAAGGTCGACAAGT phtB.seq  
1309 TTACTAGCAAGAATTCAACCAAGATTTACTTGATAATAAAGGTCGACAAGT phtD.SEQ  
1101 - phtE.SEQ

Figure 7(e)

TCATTTTGAGGCTT GATAACCTGTTGGAACGACTCAAGGATGTCTCAA Majority  
1410 1420 1430 1440 1450

1446 TGATTTTCCAAGCCTTAGACAAATTATTAGAACGCTTGAAATGATGAATCGA phtA.SEQ  
1338 TGATTTTGAAGCCTTTGGATAAACCTGTTGGAACGACTCAAGGATGTCTCAA phtB.seq  
1359 TGATTTTGAAGCCTTTGGATAAACCTGTTGGAACGACTCAAGGATGTCCCAA phtD.SEQ  
1107 ----- phtE.SEQ

GTGATAAAGTCAAGTTAGTGGATGATATTCTTGCCTTCTTAGCTCCGATT Majority  
1460 1470 1480 1490 1500

1496 CTAATAAAGAAAAAATTGGTAGATGATTTATTGGCATTCTTAGCACCAATT phtA.SEQ  
1388 GTGATAAAGTCAAGTTAGTGGAGATATTCTTGCCTTCTTAGCTCCGATT phtB.seq  
1409 GTGATAAAGTCAAGTTAGTGGATGATATTCTTGCCTTCTTAGCTCCGATT phtD.SEQ  
1107 ----- phtE.SEQ

CGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGA Majority  
1510 1520 1530 1540 1550

1546 ACCCATCCAGAGCGACTTGGCAAACCAAATTCTCAAATTGAGTATACTGA phtA.SEQ  
1438 CGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGA phtB.seq  
1459 CGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGA phtD.SEQ  
1115 ----- phtE.SEQ

TGATGAGATTCAAGTAGCCAAAGTTGGCAGGCCAAGTACACAGCATCAGATG Majority  
1560 1570 1580 1590 1600

1596 AGACGAAAGTTTCGTATTGCTCAATTAGCTGATAAGTATACAAACGTCAGATG phtA.SEQ  
1488 TGATGAGATTCAAGTAGCCAAAGTTGGCAGGCCAAGTACACAGCAGAAAGACG phtB.seq  
1509 TGATGAGATTCAAGTAGCCAAAGTTGGCAGGCCAAGTACACAGCAGAAAGACG phtD.SEQ  
1115 ----- phtE.SEQ

GTTATATTTTTTGTATCCTCGTGATATAACCAGTGATGAGGGGGGATGCCCTAT Majority  
1610 1620 1630 1640 1650

1646 GTTACATTTTTTGTATGAAACATGATATAATCAGTGATGAAGGAGATGCATAT phtA.SEQ  
1538 GTTATATCTTTGTATCCTCGTGATATAACCAGTGATGAGGGGGGATGCCCTAT phtB.seq  
1559 GTTATATCTTTGTATCCTCGTGATATAACCAGTGATGAGGGGGGATGCCCTAT phtD.SEQ  
1127 GTTATATTTTTTAATCC ----- phtE.SEQ

GTAACCTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTTGTG Majority  
1660 1670 1680 1690 1700

1696 GTAACGCTTCATATGGGCCATAGTCACTGGATTGGAAAAAGATAGCCTTTTC phtA.SEQ  
1588 GTAACCTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTTGTG phtB.seq  
1609 GTAACCTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTTGTG phtD.SEQ  
1143 ----- phtE.SEQ

TGAAGCTGAGAGAGCGGCAAGCCAGGCTTATGCTAAAGAGAAAGGTTTGA Majority  
1710 1720 1730 1740 1750

1746 TGATAAGGAAAAAAGTTGCAAGCTCAAGCCTATACTAAAGAAAAAGGTATCC phtA.SEQ  
1638 TGAAGCTGAGAGAGCGGCAAGCCAGGCTTATGCTRAAGAGAAAGGTTTGA phtB.seq  
1659 TGAAGCTGAGAGAGCGGCAAGCCAGGCTTATGCTAAAGAGAAAGGTTTGA phtD.SEQ  
1153 ----- phtE.SEQ



Figure 7(f)

CCCCCTCCTTTCGACAG JCATCAGGATTTCAGGAAATACTGAGGCAAAAGGA Majority  
1760 1770 1780 1790 1800

1796 TACCTCCATCTCCAGACGCGAGATGTTAAAGCAAATCCAACCTGGAGATAGT phtA.SEQ  
1688 CCCCTCCTTTCGACAGACCATCAGGATTTCAGGAAATACTGAGGCAAAAGGA phtB.seq  
1709 CCCCTCCTTTCGACAGACCATCAGGATTTCAGGAAATACTGAGGCAAAAGGA phtD.SEQ  
1167 ----- phtE.SEQ

GCAGAAGCTATCTACAACCGXGTGAAAGCAGCTAAGAAGGTGCCACTTGA Majority  
1810 1820 1830 1840 1850

1846 GCAGCAGCTATTTACAATCGTGTGAAAGGGGAAAAACGAATTCCACTCGT phtA.SEQ  
1738 GCAGAAGCTATCTACAACCGHGTGAAAGCAGCTAAGAAGGTGCCACTTGA phtB.seq  
1759 GCAGAAGCTATCTACAACCGGTGAAAGCAGCTAAGAAGGTGCCACTTGA phtD.SEQ  
1167 -----TACAGCT----- phtE.SEQ

TCGTATGCCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTT Majority  
1860 1870 1880 1890 1900

1896 TCGACTTCCATATATGTTGAGCATACAGTTGAGGTTAAAAACGGTAATT phtA.SEQ  
1788 TCGTATGCCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTT phtB.seq  
1809 TCGTATGCCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTT phtD.SEQ  
1174 -----TATATTGTAAGA----- phtE.SEQ

TAATCATACCTCATTATGATCATTACCATAACATTAAATTTGAGTGTTT Majority  
1910 1920 1930 1940 1950

1946 TGATTATTCTCATAAAGGATCATTACCATAATATTTAAATTTGCTTGGTTT phtA.SEQ  
1838 TAATCATACCTCATTATGACCATTACCATAACATCAAAATTTGAGTGTTT phtB.seq  
1859 TAATCATACCTCATTATGACCATTACCATAACATCAAAATTTGAGTGTTT phtD.SEQ  
1186 -----CATGGTGATCATTTCATTACATT----- phtE.SEQ

GACGAAGGCCTTTTATGAGGCACCTAAGGGGTATACTCTTGAGGATCTTTT Majority  
1960 1970 1980 1990 2000

1996 GATGATCACACATACAAAGCTCCAAATGGCTATACCTTGGGAAGATTTGTT phtA.SEQ  
1888 GACGAAGGCCTTTTATGAGGCACCTAAGGGGTATACTCTTGAGGATCTTTT phtB.seq  
1909 GACGAAGGCCTTTTATGAGGCACCTAAGGGGTATACTCTTGAGGATCTTTT phtD.SEQ  
1210 -----CCAAA----- phtE.SEQ

GCGGACTGTCAAAGTACTATGTCGAACATCCAGACGAACGTCGCGATTTCAG Majority  
2010 2020 2030 2040 2050

2046 TCGGACGATTAAAGTACTACGTAGAACACCCCTGACGAACGTCACACATTCTA phtA.SEQ  
1938 GCGGACTGTCAAAGTACTATGTCGAACATCCAAACGAACGTCGCGATTTCAG phtB.seq  
1959 GCGGACTGTCAAAGTACTATGTCGAACATCCAAACGAACGTCGCGATTTCAG phtD.SEQ  
1215 -----ATCAAAT--CAAATTGGGCAACC-GAC-----TCT--TCCAA phtE.SEQ

ATAATGTTTTTGGTTAACGCTAGCGACCATGTTTTXA-AAACAAGAAAGAT Majority  
2060 2070 2080 2090 2100

2096 ATGATGGATGGGGCAATGCCAGTGAGCATGTGTT--AGGCAAGAAAGAC phtA.SEQ  
1988 ATAATGTTTTTGGTTAACGCTAGCGACCATGTTTCAAAGAAACAAAAATGGT phtB.seq  
2009 ATAATGTTTTTGGTTAACGCTAGCGACCATGTTTCGTAAAAATTAAGGTAGAC phtD.SEQ  
1247 ACAATAG-TCTAGCAACACCTTCT-CCATCTCTTC-----CAA-----T phtE.SEQ

Figure 7(g)

C A A G C C A G T A A A C C T A A T G A A G A T G A G A A A C A T G A C C A A G T A A G - G A G - - Majority  
2110 2120 2130 2140 2150

2143 C A - - - - - C A G T G A A G A T - - - - - C C A A A T A A G - - - - - phtA.SEQ  
2038 C A A G C T G A T A - - - C C A A T C A A - A C G G A A A A - - - - A C C A A G C G A G - G A G A A phtB.seq  
2059 C A A G A C A G T A A A C C T G A T G A A G A T A A G G A A C A T G A T G A A G T A A G T G A G C C phtD.SEQ  
1284 C A A T C C A G - G A A C T T C A C - - - A T G A G A A A C A T G A - - - - - phtE.SEQ

A - C T C A - - C - G A A - - - - T G A A G A A G A - A A C C A C G - - G - T T T A A A T C C T - Majority  
2160 2170 2180 2190 2200

2164 - - - - - A A C - - - - - T T C A A A - - - - - phtA.SEQ  
2079 A C C T C A G A C A G A A A A A C C T G A G G A A G A - A A C C - - - - - C C T C phtB.seq  
2109 A A C T C A C C C T G A A T C T G A T G A A A A G A G A A T C A C G C T G G T T T A A A T C C T T phtD.SEQ  
1314 - - - - - A G A A G A T G G A T A C G - - G A T T T G A - T G C T - phtE.SEQ

- A G C A G A T A A A C C C T A T A A G C C A G - - A C - - - - - A - A C - - A - - - A Majority  
2210 2220 2230 2240 2250

2173 - - G C G G A T G A A - - - - G A G C C A G - - - - - phtA.SEQ  
2114 G A G A A G A G A A A C C G C A - A A G C G A G A A A C C A G A G T C T C C A A A A C C A A C A G A phtB.seq  
2159 C A G C A G A T A A T C T T T A T A A A C C A A G C A C T G A T A C G G A A G A G A C A G A G G A A phtD.SEQ  
1339 - - - - - A A T C G T A T T A T C - - - - - phtE.SEQ

G - A G C T G G A G G A A X C A C C A G A T G A G T C A G A A G T X C C T C A A G T A G A G A C T G Majority  
2260 2270 2280 2290 2300

2189 - - - - T A G A G G A A A C A C C T G C T G A G C C A G A A G T C C C T C A A G T A G A G A C T G phtA.SEQ  
2163 G G A A C C A G A A G A A T C A C C A G A G G A A T C A G A A G A A C C T C A G G T C G A G A C T G phtB.seq  
2209 G A A G C T G A A G A T A C C A C - A G A T G A G G C T G A A A T T C C T C A A G T A G A G A A T T phtD.SEQ  
1351 - - - G C T G A A G A - - - - - T G A A T C - - - - - phtE.SEQ

A A A A X G T T G A A G C X A A A C T X A X A G A X G C X G A G G T T T T G C T T G X A A A A G T C Majority  
2310 2320 2330 2340 2350

2234 A A A A A G T A G A A G C C C A A C T C A A A G A A G C A G A A G T T T T G C T T G C G A A A G T A phtA.SEQ  
2213 A A A A G G T T G A A G A A A A A C T G A G A G A G C T G A A G A T T T A C T T G G A A A A A T C phtB.seq  
2258 C T G T T A T T A A C G C T A A G A T A G C A G A T G C G A G G C C T T G C T A G A A A A A G T A phtD.SEQ  
1365 - - - - - A G G T T T T G - - - - - T C phtE.SEQ

A C G G A T C C T A G T A T X A A A X C C A A T G C X A C G G A G A C T C T X A C T G G T T T A A A Majority  
2360 2370 2380 2390 2400

2284 A C G G A T T C T A G T C T G A A A G C C A A T G C A A C A G A A A C T C T A G C T G G T T T A C G phtA.SEQ  
2263 C A G G A T C C A A T T A T C A A G T C C A A T G C C A A A G A G A C T C T C A C A G G A T T A A A phtB.seq  
2308 A C A G A T C C T A G T A T T A G A C A A A A T G C T A T G G A G A C A T T G A C T G G T C T A A A phtD.SEQ  
1375 A T G A G T C - - - - - A C G G A G A C C - - - - - phtE.SEQ

A A A T A A T T T X C T T C T T G G A A C X A A G G A T A A T A A T A C T A T T T T G G C A G A A G Majority  
2410 2420 2430 2440 2450

2334 A A A T A A T T T G A C T C T T C A A A T T A T G G A T A A C A A T A G T A T C A T G G C A G A A G phtA.SEQ  
2313 A A A T A A T T T A C T A T T T G G C A C C C A G G A C A A C A A T A C T A T T A T G G C A G A A G phtB.seq  
2358 A A G T A G T C T T C T T C T C G G A A C G A A A G A T A A T A A C A C T A T T T C A G C A G A A G phtD.SEQ  
1391 - - - - - A C A A T - - C A T T A T T T C T T C A - - - - phtE.SEQ

Figure 7(h)

```
CAGAAAGACTATTGGCTTTGTTAAAGGAGAGTAAXT-AAGGT-----CTT Majority
      2450      2470      2480      2490      2500
2384 CAGAAAAATTACTTGCCTTGTTAAAAAGGAAGTAATC-----CTT phtA.SEQ
2363 CTGAAAAACTATTGGCTTTATTAAAGGAGAGTAAGTAAGGTAGAAAGCTT phtB.seq
2408 TAGATAGTCTCTTGGCTTTGTTAAAAAGAAAGT-----C phtD.SEQ
1409 -AGAAAGGACT--TGAC-----AGAAAGAGCAAAATTAAGGT----- phtE.SEQ


AA--GCG--TCTGGC-CCTA-G-CAA-AA-A-T--TATGGXAAAAGCTXA Majority
      2510      2520      2530      2540      2550
2423 CA-----TCTG-----TAAG-----TAAGGAAAAAAT--- phtA.SEQ
2413 AAGGGCGAATTGTCACCCAGGACAACAATACTATTATGGCAGAAAGCTGA phtB.seq
2441 AA-----CCGGCTCCTA-----TATAGTAAAAGCTTA phtD.SEQ
1440 ---GCG-----CAAAAACATT---TAG phtE.SEQ

AAAACTAXX
Majority


2445 -AAACTAA
2463 AAAACTATT
2468 AG-----CC
1455
```

## Figure 8


### A. Strain SJ2 (serotype 6B)



### B. Strain EF6796 (serotype 6A)



### C. Strain EF5668 (serotype 4)



## SEQUENCE LISTING

<110> Johnson, Leslie S.  
Koenig, Scott  
Adamou, John E.

<120> Streptococcus Pneumoniae and Immunogenic Fragments for  
Vaccines

<130> 469201-444

<140>

<141>

<150> 60/113,048

<151> 1998-12-21

<160> 11

<170> PatentIn Ver. 2.0

<210> 1

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Forward primer  
used in amplification of the Sp36 gene sequence.

<400> 1

atcggatcct tcttacgagt tgggactgta tcaagc

36

<210> 2

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Forward primer  
used in amplification of the Sp36 gene sequence.

<400> 2

atcggatcca ctgtatcaag ctagaacggt taagg

35

<210> 3

<211> 40

<212> DNA

## &lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Reverse primer  
used in amplification of the Sp36 gene sequence.

&lt;400&gt; 3

agtcgaagctt gtttattttt tccttactta cagatgaagg

40

&lt;210&gt; 4

&lt;211&gt; 838

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pneumoniae

&lt;400&gt; 4

Met Lys Ile Asn Lys Lys Tyr Leu Ala Gly Ser Val Ala Val Leu Ala  
1 5 10 15

Leu Ser Val Cys Ser Tyr Glu Leu Gly Arg His Gln Ala Gly Gln Val  
20 25 30

Lys Lys Glu Ser Asn Arg Val Ser Tyr Ile Asp Gly Asp Gln Ala Gly  
35 40 45

Gln Lys Ala Glu Asn Leu Thr Pro Asp Glu Val Ser Lys Arg Glu Gly  
50 55 60

Ile Asn Ala Glu Gln Ile Val Ile Lys Ile Thr Asp Gln Gly Tyr Val  
65 70 75 80

Thr Ser His Gly Asp His Tyr His Tyr Tyr Asn Gly Lys Val Pro Tyr  
85 90 95

Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Lys Asp Pro Asn Tyr Gln  
100 105 110

Leu Lys Asp Ser Asp Ile Val Asn Glu Ile Lys Gly Gly Tyr Val Ile  
115 120 125

Lys Val Asp Gly Lys Tyr Tyr Val Tyr Leu Lys Asp Ala Ala His Ala  
130 135 140

Asp Asn Ile Arg Thr Lys Glu Glu Ile Lys Arg Gln Lys Gln Glu His  
145 150 155 160

Ser His Asn His Gly Gly Gly Ser Asn Asp Gln Ala Val Val Ala Ala  
165 170 175

Arg Ala Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Asn Ala  
 180 185 190  
 Ser Asp Ile Ile Glu Asp Thr Gly Asp Ala Tyr Ile Val Pro His Gly  
 195 200 205  
 Asp His Tyr His Tyr Ile Pro Lys Asn Glu Leu Ser Ala Ser Glu Leu  
 210 215 220  
 Ala Ala Ala Glu Ala Tyr Trp Asn Gly Lys Gln Gly Ser Arg Pro Ser  
 225 230 235 240  
 Ser Ser Ser Ser Tyr Asn Ala Asn Pro Ala Gln Pro Arg Leu Ser Glu  
 245 250 255  
 Asn His Asn Leu Thr Val Thr Pro Thr Tyr His Gln Asn Gln Gly Glu  
 260 265 270  
 Asn Ile Ser Ser Leu Leu Arg Glu Leu Tyr Ala Lys Pro Leu Ser Glu  
 275 280 285  
 Arg His Val Glu Ser Asp Gly Leu Ile Phe Asp Pro Ala Gln Ile Thr  
 290 295 300  
 Ser Arg Thr Ala Arg Gly Val Ala Val Pro His Gly Asn His Tyr His  
 305 310 315 320  
 Phe Ile Pro Tyr Glu Gln Met Ser Glu Leu Glu Lys Arg Ile Ala Arg  
 325 330 335  
 Ile Ile Pro Leu Arg Tyr Arg Ser Asn His Trp Val Pro Asp Ser Arg  
 340 345 350  
 Pro Glu Gln Pro Ser Pro Gln Ser Thr Pro Glu Pro Ser Pro Ser Pro  
 355 360 365  
 Gln Pro Ala Pro Asn Pro Gln Pro Ala Pro Ser Asn Pro Ile Asp Glu  
 370 375 380  
 Lys Leu Val Lys Glu Ala Val Arg Lys Val Gly Asp Gly Tyr Val Phe  
 385 390 395 400  
 Glu Glu Asn Gly Val Ser Arg Tyr Ile Pro Ala Lys Asp Leu Ser Ala  
 405 410 415  
 Glu Thr Ala Ala Gly Ile Asp Ser Lys Leu Ala Lys Gln Glu Ser Leu  
 420 425 430

Ser His Lys Leu Gly Ala Lys Lys Thr Asp Leu Pro Ser Ser Asp Arg  
 435 440 445

Glu Phe Tyr Asn Lys Ala Tyr Asp Leu Leu Ala Arg Ile His Gln Asp  
 450 455 460

Leu Leu Asp Asn Lys Gly Arg Gln Val Asp Phe Glu Ala Leu Asp Asn  
 465 470 475 480

Leu Leu Glu Arg Leu Lys Asp Val Pro Ser Asp Lys Val Lys Leu Val  
 485 490 495

Asp Asp Ile Leu Ala Phe Leu Ala Pro Ile Arg His Pro Glu Arg Leu  
 500 505 510

Gly Lys Pro Asn Ala Gln Ile Thr Tyr Thr Asp Asp Glu Ile Gln Val  
 515 520 525

Ala Lys Leu Ala Gly Lys Tyr Thr Thr Glu Asp Gly Tyr Ile Phe Asp  
 530 535 540

Pro Arg Asp Ile Thr Ser Asp Glu Gly Asp Ala Tyr Val Thr Pro His  
 545 550 555 560

Met Thr His Ser His Trp Ile Lys Lys Asp Ser Leu Ser Glu Ala Glu  
 565 570 575

Arg Ala Ala Ala Gln Ala Tyr Ala Lys Glu Lys Gly Leu Thr Pro Pro  
 580 585 590

Ser Thr Asp His Gln Asp Ser Gly Asn Thr Glu Ala Lys Gly Ala Glu  
 595 600 605

Ala Ile Tyr Asn Arg Val Lys Ala Ala Lys Lys Val Pro Leu Asp Arg  
 610 615 620

Met Pro Tyr Asn Leu Gln Tyr Thr Val Glu Val Lys Asn Gly Ser Leu  
 625 630 635 640

Ile Ile Pro His Tyr Asp His Tyr His Asn Ile Lys Phe Glu Trp Phe  
 645 650 655

Asp Glu Gly Leu Tyr Glu Ala Pro Lys Gly Tyr Thr Leu Glu Asp Leu  
 660 665 670

Leu Ala Thr Val Lys Tyr Tyr Val Glu His Pro Asn Glu Arg Pro His  
 675 680 685



Ser Asp Asn Gly Phe Gly Asn Ala Ser Asp His Val Arg Lys Asn Lys  
690 695 700

Val Asp Gln Asp Ser Lys Pro Asp Glu Asp Lys Glu His Asp Glu Val  
705 710 715 720

Ser Glu Pro Thr His Pro Glu Ser Asp Glu Lys Glu Asn His Ala Gly  
725 730 735

Leu Asn Pro Ser Ala Asp Asn Leu Tyr Lys Pro Ser Thr Asp Thr Glu  
740 745 750

Glu Thr Glu Glu Glu Ala Glu Asp Thr Thr Asp Glu Ala Glu Ile Pro  
755 760 765

Gln Val Glu Asn Ser Val Ile Asn Ala Lys Ile Ala Asp Ala Glu Ala  
770 775 780

Leu Leu Glu Lys Val Thr Asp Pro Ser Ile Arg Gln Asn Ala Met Glu  
785 790 795 800

Thr Leu Thr Gly Leu Lys Ser Ser Leu Leu Leu Gly Thr Lys Asp Asn  
805 810 815

Asn Thr Ile Ser Ala Glu Val Asp Ser Leu Leu Ala Leu Leu Lys Glu  
820 825 830

Ser Gln Pro Ala Pro Ile  
835

<210> 5

<211> 2531

<212> DNA

<213> Streptococcus pneumoniae

<400> 5

atgaaaatta ataaaaaata tctagcaggt tcagtggcag tccttgccct aagtgtttgt 60  
tcctatgaac ttggtcgtca ccaagctggt caggttaaga aagagtctaa tcgagtttct 120  
tatatagatg gtgatcaggc tggtaaaaag gcagaaaact tgacaccaga tgaagtcagt 180  
aagagggagg ggatcaacgc cgaacaaatc gtcatacaga ttacggatca aggttatgtg 240  
acctctcatg gagaccatta tcattactat aatggcaagg tcccttatga tgccatcatc 300  
agtgaagagc tcctcatgaa agatccgaat tatcagttga aggattcaga cattgtcaat 360  
gaaatcaagg gtggttatgt tatcaaggta gatggaaaat actatgttta ccttaaggat 420  
gcagctcatg cggataatat tcggacaaaa gaagagatta aacgtcagaa gcaggaacac 480  
agtcataatc acgggggttg ttctaacgat caagcagtag ttgcagccag agcccaagga 540  
cgctatacaa cggatgatgg ttatatcttc aatgcactctg atatcattga ggacacgggt 600  
gatgcttata tcgttctca cggcgaccat taccattaca ttcctaagaa tgagttatca 660

```

gctagcgagt tagctgctgc agaagcctat tggaaatggga agcaggggatc tcgtccttct 720
tcaagttcta gttataatgc aaatccagct caaccaagat tgtcagagaa ccacaatctg 780
actgtcactc caacttatca tcaaaatcaa ggggaaaaca tttcaagcct tttacgtgaa 840
ttgtatgcta aacccttatc agaacgccat gtggaatctg atggccttat tttcgacca 900
gcgcaaatca caagtcgaac cgccagaggt gtagctgtcc ctcatggtaa ccattaccac 960
tttatccctt atgaacaaat gtctgaattg gaaaaacgaa ttgctcgtat tattccctt 1020
cgttatcggt caaaccattg ggtaccagat tcaagaccag aacaaccaag tccacaatcg 1080
actccggaac ctagtccaag tccgcaacct gcaccaaacc ctcaaccagc tccaagcaat 1140
ccaattgatg agaaattggt caaagaagct gttcgaaaag taggcgatgg ttatgtcttt 1200
gaggagaatg gagtttctcg ttatatccca gccaaaggatc tttcagcaga aacagcagca 1260
ggcattgata gcaaaactggc caagcaggaa agtttatctc ataagctagg agctaagaaa 1320
actgacctcc catctagtga tcgagaattt tacaataagg cttatgactt actagcaaga 1380
attcaccaag atttacttga taataaaggt cgacaagttg attttgaggc tttggataac 1440
ctggttgaac gactcaagga tgcctcaagt gataaagtca agttagtggg tgatattctt 1500
gccttcttag ctccgattcg tcatccagaa cgtttaggaa aaccaaattgc gcaaaattacc 1560
tacactgatg atgagattca agtagccaag ttggcaggca agtacacaac agaagacggg 1620
tatatctttg atcctcgtga tataaccagt gatgaggggg atgcctatgt aactccacat 1680
atgacccata gccactggat taaaaaagat agtttgtctg aagctgagag agcggcagcc 1740
caggcttatg ctaaagagaa aggtttgacc cctccttcga cagaccatca ggattcagga 1800
aatactgagg caaaaggagc agaagctatc tacaaccgcg tgaaagcagc taagaagggtg 1860
ccacttgatc gtatgcctta caatcttcaa tatactgtag aagtcaaaaa cggtagttta 1920
atcatacctc attatgacca ttaccataac atcaaatgtg agtggtttga cgaaggcctt 1980
tatgaggcac ctaaggggta tactcttgag gatcttttgg cgactgtcaa gtactatgtc 2040
gaacatccaa acgaacgtcc gcattcagat aatgggtttg gtaacgctag cgaccatgtt 2100
cgtaaaaaata aggtagacca agacagtaaa cctgatgaag ataaggaaca tgatgaagta 2160
agtgagccaa ctccacctga atctgatgaa aaagagaatc acgctgggtt aaatccttca 2220
gcagataatc tttataaacc aagcactgat acggaagaga cagaggaaga agctgaagat 2280
accacagatg aggctgaaat tcctcaagta gagaattctg ttattaacgc taagatagca 2340
gatgcggagg ccttgctaga aaaagtaaca gacccatgta ttagacaaaa tgctatggag 2400
acattgactg gtctaaaaag tagtcttctt ctccggaacga aagataataa cactatttca 2460
gcagaagtag atagtctctt ggctttgtta aaagaaagtc aaccggctcc tatatagtaa 2520
aagcttaagc c

```

2531

&lt;210&gt; 6

&lt;211&gt; 484

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pneumoniae

&lt;400&gt; 6

```

Met Lys Phe Ser Lys Lys Tyr Ile Ala Ala Gly Ser Ala Val Ile Val
  1                      5                      10                      15

```

```

Ser Leu Ser Leu Cys Ala Tyr Ala Leu Asn Gln His Arg Ser Gln Glu
          20                      25                      30

```

```

Asn Lys Asp Asn Asn Arg Val Ser Tyr Val Asp Gly Ser Gln Ser Ser
      35                      40                      45

```

Gln Lys Ser Glu Asn Leu Thr Pro Asp Gln Val Ser Gln Lys Glu Gly  
 50 55 60

Ile Gln Ala Glu Gln Ile Val Ile Lys Ile Thr Asp Gln Gly Tyr Val  
 65 70 75 80

Thr Ser His Gly Asp His Tyr His Tyr Tyr Asn Gly Lys Val Pro Tyr  
 85 90 95

Asp Ala Leu Phe Ser Glu Glu Leu Leu Met Lys Asp Pro Asn Tyr Gln  
 100 105 110

Leu Lys Asp Ala Asp Ile Val Asn Glu Val Lys Gly Gly Tyr Ile Ile  
 115 120 125

Lys Val Asp Gly Lys Tyr Tyr Val Tyr Leu Lys Asp Ala Ala His Ala  
 130 135 140

Asp Asn Val Arg Thr Lys Asp Glu Ile Asn Arg Gln Lys Gln Glu His  
 145 150 155 160

Val Lys Asp Asn Glu Lys Val Asn Ser Asn Val Ala Val Ala Arg Ser  
 165 170 175

Gln Gly Arg Tyr Thr Thr Asn Asp Gly Tyr Val Phe Asn Pro Ala Asp  
 180 185 190

Ile Ile Glu Asp Thr Gly Asn Ala Tyr Ile Val Pro His Gly Gly His  
 195 200 205

Tyr His Tyr Ile Pro Lys Ser Asp Leu Ser Ala Ser Glu Leu Ala Ala  
 210 215 220

Ala Lys Ala His Leu Ala Gly Lys Asn Met Gln Pro Ser Gln Leu Ser  
 225 230 235 240

Tyr Ser Ser Thr Ala Ser Asp Asn Asn Thr Gln Ser Val Ala Lys Gly  
 245 250 255

Ser Thr Ser Lys Pro Ala Asn Lys Ser Glu Asn Leu Gln Ser Leu Leu  
 260 265 270

Lys Glu Leu Tyr Asp Ser Pro Ser Ala Gln Arg Tyr Ser Glu Ser Asp  
 275 280 285

Gly Leu Val Phe Asp Pro Ala Lys Ile Ile Ser Arg Thr Pro Asn Gly  
 290 295 300

Val Ala Ile Pro His Gly Asp His Tyr His Phe Ile Pro Tyr Ser Lys  
305 310 315 320

Leu Ser Ala Leu Glu Glu Lys Ile Ala Arg Met Val Pro Ile Ser Gly  
325 330 335

Thr Gly Ser Thr Val Ser Thr Asn Ala Lys Pro Asn Glu Val Val Ser  
340 345 350

Ser Leu Gly Ser Leu Ser Ser Asn Pro Ser Ser Leu Thr Thr Ser Lys  
355 360 365

Glu Leu Ser Ser Ala Ser Asp Gly Tyr Ile Phe Asn Pro Lys Asp Ile  
370 375 380

Val Glu Glu Thr Ala Thr Ala Tyr Ile Val Arg His Gly Asp His Phe  
385 390 395 400

His Tyr Ile Pro Lys Ser Asn Gln Ile Gly Gln Pro Thr Leu Pro Asn  
405 410 415

Asn Ser Leu Ala Thr Pro Ser Pro Ser Leu Pro Ile Asn Pro Gly Thr  
420 425 430

Ser His Glu Lys His Glu Glu Asp Gly Tyr Gly Phe Asp Ala Asn Arg  
435 440 445

Ile Ile Ala Glu Asp Glu Ser Gly Phe Val Met Ser His Gly Asp His  
450 455 460

Asn His Tyr Phe Phe Lys Lys Asp Leu Thr Glu Glu Gln Ile Lys Val  
465 470 475 480

Arg Lys Asn Ile

<210> 7

<211> 1455

<212> DNA

<213> Streptococcus pneumoniae

<400> 7

atgaaattta gtaaaaaata tatagcagct ggatcagctg ttatcgtatc cttgagtcta 60  
tgtgcctatg cactaaacca gcatcgttcg caggaaaata aggacaataa tcgtgtctct 120  
tatgtggatg gcagccagtc aagtcagaaa agtgaaaact tgacaccaga ccaggttagc 180  
cagaaagaag gaattcaggc tgagcaaatt gtaatcaaaa ttacagatca gggctatgta 240  
acgtcacacg gtgaccacta tcattactat aatgggaaag ttccttatga tgcctctttt 300

```

agtgaagaac tcttgatgaa ggatccaaac tatcaactta aagacgctga tattgtcaat 360
gaagtcaagg gtggttatat catcaaggct gatggaaaat attatgtcta cctgaaagat 420
gcagctcatg ctgataatgt tcgaactaaa gatgaaatca atcgtcaaaa acaagaacat 480
gtcaaagata atgagaagggt taactctaata gttgctgtag caaggctctca gggacgatat 540
acgacaaatg atgggttatgt ctttaaatcca gctgatatta tcgaagatac gggtaaatgct 600
tatatcggtc ctcattggagg tcactatcac tacattccca aaagcgattt atctgctagt 660
gaattagcag cagctaaagc acatctggct ggaaaaaata tgcaaccgag tcagttaagc 720
tattcttcaa cagctagtga caataacacg caatctgtag caaaaggatc aactagcaag 780
ccagcaaata aatctgaaaa tctccagagt cttttgaagg aactctatga ttcacctagc 840
gccccacgtt acagtgaatc agatggcctg gtctttgacc ctgctaagat tatcagtcgt 900
acaccaaatg gagttgcgat tccgcatggc gaccattacc actttattcc ttacagcaag 960
ctttctgcct tagaagaaaa gattgccaga atgggtgccta tcagtggaaac tggttctaca 1020
gtttctacaa atgcaaaaacc taatgaagta gtgtctagtc taggcagtct ttcaagcaat 1080
ccttcttctt taacgacaag taaggagctc tcttcagcat ctgatggta tatttttaaat 1140
ccaaaagata tcggtgaaga aacggctaca gcttatattg taagacatgg tgatcatttc 1200
cattacattc caaaatcaaa tcaaattggg caaccgactc ttccaaacaa tagtctagca 1260
acaccttctc catctcttcc aatcaatcca ggaacttcac atgagaaaca tgaagaagat 1320
ggatacggat ttgatgctaa tcgtattatc gctgaagatg aatcagggtt tgatcatgagt 1380
cacggagacc acaatcatta tttcttcaag aaggacttga cagaagagca aattaagggtg 1440
cgcaaaaaaca ttttag 1455

```

&lt;210&gt; 8

&lt;211&gt; 819

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pneumoniae

&lt;400&gt; 8

```

Met Lys Ile Asn Lys Lys Tyr Leu Val Gly Ser Ala Ala Ala Leu Ile
  1               5               10              15

Leu Ser Val Cys Ser Tyr Glu Leu Gly Leu Tyr Gln Ala Arg Thr Val
          20              25              30

Lys Glu Asn Asn Arg Val Ser Tyr Ile Asp Gly Lys Gln Ala Thr Gln
      35              40              45

Lys Thr Glu Asn Leu Thr Pro Asp Glu Val Ser Lys Arg Glu Gly Ile
      50              55              60

Asn Ala Glu Gln Ile Val Ile Lys Ile Thr Asp Gln Gly Tyr Val Thr
      65              70              75              80

Ser His Gly Asp His Tyr His Tyr Tyr Asn Gly Lys Val Pro Tyr Asp
          85              90              95

Ala Ile Ile Ser Glu Glu Leu Leu Met Lys Asp Pro Asn Tyr Lys Leu
      100              105              110

```

Lys Asp Glu Asp Ile Val Asn Glu Val Lys Gly Gly Tyr Val Ile Lys  
 115 120 125  
 Val Asp Gly Lys Tyr Tyr Val Tyr Leu Lys Asp Ala Ala His Ala Asp  
 130 135 140  
 Asn Val Arg Thr Lys Glu Glu Ile Asn Arg Gln Lys Gln Glu His Ser  
 145 150 155 160  
 Gln His Arg Glu Gly Gly Thr Pro Arg Asn Asp Gly Ala Val Ala Leu  
 165 170 175  
 Ala Arg Ser Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Asn  
 180 185 190  
 Ala Ser Asp Ile Ile Glu Asp Thr Gly Asp Ala Tyr Ile Val Pro His  
 195 200 205  
 Gly Asp His Tyr His Tyr Ile Pro Lys Asn Glu Leu Ser Ala Ser Glu  
 210 215 220  
 Leu Ala Ala Ala Glu Ala Phe Leu Ser Gly Arg Gly Asn Leu Ser Asn  
 225 230 235 240  
 Ser Arg Thr Tyr Arg Arg Gln Asn Ser Asp Asn Thr Ser Arg Thr Asn  
 245 250 255  
 Trp Val Pro Ser Val Ser Asn Pro Gly Thr Thr Asn Thr Asn Thr Ser  
 260 265 270  
 Asn Asn Ser Asn Thr Asn Ser Gln Ala Ser Gln Ser Asn Asp Ile Asp  
 275 280 285  
 Ser Leu Leu Lys Gln Leu Tyr Lys Leu Pro Leu Ser Gln Arg His Val  
 290 295 300  
 Glu Ser Asp Gly Leu Val Phe Asp Pro Ala Gln Ile Thr Ser Arg Thr  
 305 310 315 320  
 Ala Arg Gly Val Ala Val Pro His Gly Asp His Tyr His Phe Ile Pro  
 325 330 335  
 Tyr Ser Gln Met Ser Glu Leu Glu Glu Arg Ile Ala Arg Ile Ile Pro  
 340 345 350  
 Leu Arg Tyr Arg Ser Asn His Trp Val Pro Asp Ser Arg Pro Glu Gln  
 355 360 365

Pro Ser Pro Gln Pro Thr Pro Glu Pro Ser Pro Gly Pro Gln Pro Ala  
 370 375 380

Pro Asn Leu Lys Ile Asp Ser Asn Ser Ser Leu Val Ser Gln Leu Val  
 385 390 395 400

Arg Lys Val Gly Glu Gly Tyr Val Phe Glu Glu Lys Gly Ile Ser Arg  
 405 410 415

Tyr Val Phe Ala Lys Asp Leu Pro Ser Glu Thr Val Lys Asn Leu Glu  
 420 425 430

Ser Lys Leu Ser Lys Gln Glu Ser Val Ser His Thr Leu Thr Ala Lys  
 435 440 445

Lys Glu Asn Val Ala Pro Arg Asp Gln Glu Phe Tyr Asp Lys Ala Tyr  
 450 455 460

Asn Leu Leu Thr Glu Ala His Lys Ala Leu Phe Glu Asn Lys Gly Arg  
 465 470 475 480

Asn Ser Asp Phe Gln Ala Leu Asp Lys Leu Leu Glu Arg Leu Asn Asp  
 485 490 495

Glu Ser Thr Asn Lys Glu Lys Leu Val Asp Asp Leu Leu Ala Phe Leu  
 500 505 510

Ala Pro Ile Thr His Pro Glu Arg Leu Gly Lys Pro Asn Ser Gln Ile  
 515 520 525

Glu Tyr Thr Glu Asp Glu Val Arg Ile Ala Gln Leu Ala Asp Lys Tyr  
 530 535 540

Thr Thr Ser Asp Gly Tyr Ile Phe Asp Glu His Asp Ile Ile Ser Asp  
 545 550 555 560

Glu Gly Asp Ala Tyr Val Thr Pro His Met Gly His Ser His Trp Ile  
 565 570 575

Gly Lys Asp Ser Leu Ser Asp Lys Glu Lys Val Ala Ala Gln Ala Tyr  
 580 585 590

Thr Lys Glu Lys Gly Ile Leu Pro Pro Ser Pro Asp Ala Asp Val Lys  
 595 600 605

Ala Asn Pro Thr Gly Asp Ser Ala Ala Ala Ile Tyr Asn Arg Val Lys  
 610 615 620

Gly Glu Lys Arg Ile Pro Leu Val Arg Leu Pro Tyr Met Val Glu His  
625 630 635 640

Thr Val Glu Val Lys Asn Gly Asn Leu Ile Ile Pro His Lys Asp His  
645 650 655

Tyr His Asn Ile Lys Phe Ala Trp Phe Asp Asp His Thr Tyr Lys Ala  
660 665 670

Pro Asn Gly Tyr Thr Leu Glu Asp Leu Phe Ala Thr Ile Lys Tyr Tyr  
675 680 685

Val Glu His Pro Asp Glu Arg Pro His Ser Asn Asp Gly Trp Gly Asn  
690 695 700

Ala Ser Glu His Val Leu Gly Lys Lys Asp His Ser Glu Asp Pro Asn  
705 710 715 720

Lys Asn Phe Lys Ala Asp Glu Glu Pro Val Glu Glu Thr Pro Ala Glu  
725 730 735

Pro Glu Val Pro Gln Val Glu Thr Glu Lys Val Glu Ala Gln Leu Lys  
740 745 750

Glu Ala Glu Val Leu Leu Ala Lys Val Thr Asp Ser Ser Leu Lys Ala  
755 760 765

Asn Ala Thr Glu Thr Leu Ala Gly Leu Arg Asn Asn Leu Thr Leu Gln  
770 775 780

Ile Met Asp Asn Asn Ser Ile Met Ala Glu Ala Glu Lys Leu Leu Ala  
785 790 795 800

Leu Leu Lys Gly Ser Asn Pro Ser Ser Val Ser Lys Glu Lys Ile Asn  
805 810 815

Lys Leu Asn

<210> 9

<211> 2451

<212> DNA

<213> Streptococcus pneumoniae

<400> 9

atgaaaatta ataagaaata ccttggttggc tctgcggcag ctttgatttt aagtgtttgt 60  
tcttacgagt tgggactgta tcaagctaga acggttaagg aaaataatcg tgtttcctat 120



```

atagatggaa aacaagcgac gcaaaaaacg gagaatttga ctctgatga ggtagcaag 180
cgtgaaggaa tcaatgctga gcaaatcgtc atcaagataa cagaccaagg ctatgtcact 240
tcacatggcg accactatca ttattacaat ggtaagggttc cttatgacgc tatcatcagt 300
gaagaattac tcatgaaaga tccaaactat aagctaaaag atgaggatat tgttaatgag 360
gtcaaggggtg gatatgttat caaggtagat ggaaaatact atgtttacct taaggatgct 420
gcccacgcgg ataacgtccg tacaaaagag gaaatcaatc gacaaaaaca agagcatagt 480
caacatcggtg aagggtggaac tccaagaaac gatgggtgctg ttgccttggc acgttcgcaa 540
ggacgctata ctacagatga tggttatata tttaatgctt ctgatatacat agaggatact 600
ggatgatgctt atatcgttcc tcatggagat cattaccatt acattcctaa gaatgagtta 660
tcagctagcg agttggctgc tgcagaagcc ttcctatctg gtcgaggaaa tctgtcaaat 720
tcaagaacct atcgccgaca aaatagcgat aacacttcaa gaacaaactg ggtaccttct 780
gtaagcaatc caggaactac aaatactaac acaagcaaca acagcaacac taacagtcaa 840
gcaagtcaaa gtaatgacat tgatagtctc ttgaaacagc tctacaaact gcctttgagt 900
caacgacatg tagaatctga tggccttgctc tttgatccag cacaaatcac aagtccaaca 960
gctagagggtg ttgcagtgcc acacggagat cattaccact tcatccctta ctctcaaagt 1020
tctgaattgg aagaacgaat cgctcgtatt attccccctc gttatcggtc aaaccattgg 1080
gtaccagatt caaggccaga acaaccaagt ccacaaccga ctccggaacc tagtccaggc 1140
ccgcaacctg caccaaactc taaaatagac tcaaattctt ctttggttag tcagctggta 1200
cgaaaagttg ggggaaggata tgtattcgaa gaaaagggca tctctcgtaa tgtctttgcg 1260
aaagatttac catctgaaac tgttaaaaaat cttgaaagca agttatcaaa acaagagagt 1320
gtttcacaca ctttaactgc taaaaaagaa aatgttgctc ctctgaccca agaattttat 1380
gataaagcat ataactctgtt aactgaggct cataaagcct tgtttgnaaa taagggtcgt 1440
aattctgatt tccaagcctt agacaaatta ttagaacgct tgaatgatga atcgactaat 1500
aaagaaaaat tggtagatga tttattggca ttcctagcac caattacca tccagagcga 1560
cttggcaaac caaattctca aattgagtat actgaagacg aagttcgtat tgctcaatta 1620
gctgataagt atacaacgtc agatgggttac atttttgatg aacatgatat aatcagtgat 1680
gaaggagatg catatgtaac gcctcatatg ggccatagtc actggattgg aaaagatagc 1740
ctttctgata aggaaaaagt tgcagctcaa gcctatacta aagaaaaagg taccctacct 1800
ccatctccag acgcagatgt taaagcaaat ccaactggag atagtgcagc agctatttac 1860
aatcgtgtga aaggggaaaa acgaattcca ctcgttcgac ttccatatat ggttgagcat 1920
acagttgagg ttaaaaacgg taatttgatt attcctcata aggatcatta ccataatatt 1980
aaatttgctt ggtttgatga tcacacatac aaagctccaa atggctatac cttggaagat 2040
ttgtttgca cgattaagta ctacgtagaa caccctgacg aacgtccaca ttctaagat 2100
ggatggggca atgccagtga gcatgtgtta ggcaagaaag accacagtga agatccaaat 2160
aagaacttca aagcggatga agagccagta gaggaacac ctgctgagcc agaagtcctt 2220
caagtagaga ctgaaaaagt agaagcccaa ctcaaagaag cagaagtttt gcttgcgaaa 2280
gtaacggatt ctagtctgaa agccaatgca acagaaactc tagctggttt acgaaataat 2340
ttgactcttc aaattatgga taacaatagt atcatggcag aagcagaaaa attacttgcg 2400
ttgttaaaag gaagtaatcc ttcactctgta agtaaggaaa aaataaacta a 2451

```

&lt;210&gt; 10

&lt;211&gt; 819

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pneumoniae

&lt;400&gt; 10

Met Lys Ile Asn Lys Lys Tyr Leu Ala Gly Ser Val Ala Val Leu Ala

1

5

10

15

Leu Ser Val Cys Ser Tyr Glu Leu Gly Arg Tyr Gln Ala Gly Gln Asp  
                   20                  25                  30

Lys Lys Glu Ser Asn Arg Val Ala Tyr Ile Asp Gly Asp Gln Ala Gly  
                   35                  40                  45

Gln Lys Ala Glu Asn Leu Thr Pro Asp Glu Val Ser Lys Arg Glu Gly  
                   50                  55                  60

Ile Asn Ala Glu Gln Ile Val Ile Lys Ile Thr Asp Gln Gly Tyr Val  
                   65                  70                  75                  80

Thr Ser His Gly Asp His Tyr His Tyr Tyr Asn Gly Lys Val Pro Tyr  
                                   85                                  90                                  95

Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Lys Asp Pro Asn Tyr Gln  
                   100                  105                  110

Leu Lys Asp Ser Asp Ile Val Asn Glu Ile Lys Gly Gly Tyr Val Ile  
                   115                  120                  125

Lys Val Asn Gly Lys Tyr Tyr Val Tyr Leu Lys Asp Ala Ala His Ala  
                   130                  135                  140

Asp Asn Ile Arg Thr Lys Glu Glu Ile Lys Arg Gln Lys Gln Glu Arg  
                   145                  150                  155                  160

Ser His Asn His Asn Ser Arg Ala Asp Asn Ala Val Ala Ala Ala Arg  
                                   165                                  170                                  175

Ala Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Asn Ala Ser  
                   180                  185                  190

Asp Ile Ile Glu Asp Thr Gly Asp Ala Tyr Ile Val Pro His Gly Asp  
                   195                  200                  205

His Tyr His Tyr Ile Pro Lys Asn Glu Leu Ser Ala Ser Glu Leu Ala  
                   210                  215                  220

Ala Ala Glu Ala Tyr Trp Asn Gly Lys Gln Gly Ser Arg Pro Ser Ser  
                   225                  230                  235                  240

Ser Ser Ser Tyr Asn Ala Asn Pro Ala Gln Pro Arg Leu Ser Glu Asn  
                   245                  250                  255

His Asn Leu Thr Val Thr Pro Thr Tyr His Gln Asn Gln Gly Glu Asn  
                   260                  265                  270

Ile Ser Ser Leu Leu Arg Glu Leu Tyr Ala Lys Pro Leu Ser Glu Arg  
 275 280 285  
 His Val Glu Ser Asp Gly Leu Ile Phe Asp Pro Ala Gln Ile Thr Ser  
 290 295 300  
 Arg Thr Ala Arg Gly Val Ala Val Pro His Gly Asn His Tyr His Phe  
 305 310 315 320  
 Ile Pro Tyr Glu Gln Met Ser Glu Leu Glu Lys Arg Ile Ala Arg Ile  
 325 330 335  
 Ile Pro Leu Arg Tyr Arg Ser Asn His Trp Val Pro Asp Ser Arg Pro  
 340 345 350  
 Glu Glu Pro Ser Pro Gln Pro Thr Pro Glu Pro Ser Pro Ser Pro Gln  
 355 360 365  
 Pro Ala Pro Ser Asn Pro Ile Asp Gly Lys Leu Val Lys Glu Ala Val  
 370 375 380  
 Arg Lys Val Gly Asp Gly Tyr Val Phe Glu Glu Asn Gly Val Ser Arg  
 385 390 395 400  
 Tyr Ile Pro Ala Lys Asp Leu Ser Ala Glu Thr Ala Ala Gly Ile Asp  
 405 410 415  
 Ser Lys Leu Ala Lys Gln Glu Ser Leu Ser His Lys Leu Gly Thr Lys  
 420 425 430  
 Lys Thr Asp Leu Pro Ser Ser Asp Arg Glu Phe Tyr Asn Lys Ala Tyr  
 435 440 445  
 Asp Leu Leu Ala Arg Ile His Gln Asp Leu Leu Asp Asn Lys Gly Arg  
 450 455 460  
 Gln Val Asp Phe Glu Ala Leu Asp Asn Leu Leu Glu Arg Leu Lys Asp  
 465 470 475 480  
 Val Ser Ser Asp Lys Val Lys Leu Val Glu Asp Ile Leu Ala Phe Leu  
 485 490 495  
 Ala Pro Ile Arg His Pro Glu Arg Leu Gly Lys Pro Asn Ala Gln Ile  
 500 505 510  
 Thr Tyr Thr Asp Asp Glu Ile Gln Val Ala Lys Leu Ala Gly Lys Tyr  
 515 520 525

Thr Ala Glu Asp Gly Tyr Ile Phe Asp Pro Arg Asp Ile Thr Ser Asp  
 530 535 540

Glu Gly Asp Ala Tyr Val Thr Pro His Met Thr His Ser His Trp Ile  
 545 550 555 560

Lys Lys Asp Ser Leu Ser Glu Ala Glu Arg Ala Ala Ala Gln Ala Tyr  
 565 570 575

Ala Glu Glu Lys Gly Leu Thr Pro Pro Ser Thr Asp His Gln Asp Ser  
 580 585 590

Gly Asn Thr Glu Ala Lys Gly Ala Glu Ala Ile Tyr Asn Arg Val Lys  
 595 600 605

Ala Ala Lys Lys Val Pro Leu Asp Arg Met Pro Tyr Asn Leu Gln Tyr  
 610 615 620

Thr Val Glu Val Lys Asn Gly Ser Leu Ile Ile Pro His Tyr Asp His  
 625 630 635 640

Tyr His Asn Ile Lys Phe Glu Trp Phe Asp Glu Gly Leu Tyr Glu Ala  
 645 650 655

Pro Lys Gly Tyr Thr Leu Glu Asp Leu Leu Ala Thr Val Lys Tyr Tyr  
 660 665 670

Val Glu His Pro Asn Glu Arg Pro His Ser Asp Asn Gly Phe Gly Asn  
 675 680 685

Ala Ser Asp His Val Gln Arg Asn Lys Asn Gly Gln Ala Asp Thr Asn  
 690 695 700

Gln Thr Glu Lys Pro Ser Glu Glu Lys Pro Gln Thr Glu Lys Pro Glu  
 705 710 715 720

Glu Glu Thr Pro Arg Glu Glu Lys Pro Gln Ser Glu Lys Pro Glu Ser  
 725 730 735

Pro Lys Pro Thr Glu Glu Pro Glu Glu Ser Pro Glu Glu Ser Glu Glu  
 740 745 750

Pro Gln Val Glu Thr Glu Lys Val Glu Glu Lys Leu Arg Glu Ala Glu  
 755 760 765

Asp Leu Leu Gly Lys Ile Gln Asp Pro Ile Ile Lys Ser Asn Ala Lys  
 770 775 780

Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp  
785 790 795 800

Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys  
805 810 815

Glu Ser Lys

<210> 11

<211> 2531

<212> DNA

<213> Streptococcus pneumoniae

<400> 11

```

atgaaaatta ataaaaaata tctagcaggt tcagtggcag tccttgcctt aagtgtttgt 60
tcctatgagc ttggacgtta ccaagctggt caggataaga aagagtctaa tcgagttgct 120
tatatagatg gtgatcaggc tgggtcaaaag gcagaaaact tgacaccaga tgaagtcagt 180
aagagggagg ggatcaacgc cgaacaaatt gttatcaaga ttacggatca aggttatgtg 240
acctctcatg gagaccatta tcattactat aatggcaagg ttcccttatga tgccatcatc 300
agtgaagagc tcctcatgaa agatccgaat tatcagttga aggattcaga cattgtcaat 360
gaaatcaagg gtggttatgt cattaaggta aacggtaaat actatgttta ccttaaggat 420
gcrctcatg cggataatat tcggacaaaa gaagagatta aacgtcagaa gcaggaacgc 480
agtcataatc ataactcaag agcagataat gctgttgctg cagccagagc ccaaggacgt 540
tatacaacgg atgatgggta tatcttcaat gcatctgata tcattgagga cacgggtgat 600
gcttatatcg ttccctcagg cgaccattac cattacattc ctaagaatga gttatcagct 660
agcgagttag ctgctgcaga agcctatttg aatgggaagc agggatctcg tccttcttca 720
agttctagtt ataatgcaa tccagctcaa ccaagattgt cagagaacca caatctgact 780
gtcactccaa cttatcatca aaatcaaggg gaaaacattt caagcctttt acgtgaattg 840
tatgctaaac cttatcaga acgcatgtg gaatctgatg gccttatttt cgaccacagc 900
caaatcacia gtcgaaccgc cagaggtgta gctgtccctc atggtaacca ttaccacttt 960
atcccttatg aacaaatgtc tgaattggaa aaacgaattg ctcgatttat tcccccttct 1020
tategttcaa accattgggt accagattca agaccagaag aaccaagtcc acaaccgact 1080
ccagaacctg gtccaagtcc gcaaccagct ccaagcaatc caattgatgg gaaattggtc 1140
aaagaagctg ttcgaaaagt aggcgatggg tatgtctttg aggagaatgg agtttctcgt 1200
tatatcccag ccaaggatct ttcagcagaa acagcagcag gcattgatag caaactggcc 1260
aagcaggaat gtttatctca taagctagga actaagaaaa ctgacctccc atctagtgat 1320
cgagaatttt acaataaggc ttatgactta ctacgaagaa ttcaccaaga ttactttgat 1380
aataaaggtc gacaagttga ttttgaggct ttggataacc tggttgaacg actcaaggat 1440
gtctcaagtg ataaagtcaa gttagtggaa gatattcttg ccttcttagc tccgatctgt 1500
catccagaac gtttaggaaa accaaatgcg caaattacct aactgatga tgagattcaa 1560
gtagccaagt tggcaggcaa gtacacagca gaagacgggt atatctttga tctctgtgat 1620
ataaccagtg atgaggggga tgcctatgta actccacata tgacctatag ccactggatt 1680
aaaaaagata gtttgtctga agctgagaga gcggcagccc aggtttatgc traagagaaa 1740
ggtttgacct ctccctcgac agaccatcag gattcaggaa atactgaggc aaaaggagca 1800
gaagctatct acaaccgmgt gaaagcagct aagaagggtg cacttgatcg tatgccttac 1860

```

```
aatcttcaat atactgtaga agtcaaaaac ggtagtttaa tcatacctca ttatgaccat 1920
taccataaca tcaaatttga gtgggttgac gaaggccttt atgaggcacc taaggggtat 1980
actcttgagg atcttttggc gactgtcaag tactatgtcg aacatccaaa cgaacgtccg 2040
cattcagata atggttttgg taacgctagc gaccatgttc aaagaaacaa aaatgggtcaa 2100
gctgatacca atcaaacgga aaaaccaagc gaggagaaac ctgagacaga aaaacctgag 2160
gaagaaaccc ctcgagaaga gaaaccgcaa agcgagaaac cagagtctcc aaaaccaaca 2220
gaggaaccag aagaatcacc agaggaatca gaagaacctc aggtcgagac tgaaaagggt 2280
gaagaaaaac tgagagaggc tgaagattta cttggaaaaa tccaggatcc aattatcaag 2340
tccaatgcca aagagactct cacaggatta aaaaataatt tactatttgg caccaggagc 2400
aacaatacta ttatggcaga agctgaaaaa ctattggctt tattaaagga gagtaagtaa 2460
aggtagaagc ttaagggcga atttggcacc caggacaaca atactattat ggcagaagct 2520
gaaaaactat t                                     2531
```



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 39/09, 39/40, A61P 31/04 // C07K 14/315</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/37105</b> <b>(43) International Publication Date:</b> 29 June 2000 (29.06.00)
<b>(21) International Application Number:</b> PCT/US99/30390 <b>(22) International Filing Date:</b> 21 December 1999 (21.12.99) <b>(30) Priority Data:</b> 60/113,048                      21 December 1998 (21.12.98)      US <b>(71) Applicant:</b> MEDIMMUNE, INC. [US/US]; 35 West Watkins Mill Road, Gaithersburg, MD 20878 (US). <b>(72) Inventors:</b> JOHNSON, Leslie, S.; 13545 Ambassador Drive, Germantown, MD 20874 (US). KOENIG, Scott; 10732 Ralston Road, Rockville, MD 20852 (US). ADAMOU, John, E.; 20822 Shamrock Glen Circle, Germantown, MD 20874 (US). <b>(74) Agents:</b> GRANT, Alan, J. et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 9 November 2000 (09.11.00)
<b>(54) Title:</b> STREPTOCOCCUS PNEUMONIAE PROTEINS AND IMMUNOGENIC FRAGMENTS FOR VACCINES <b>(57) Abstract</b> <p>A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by <i>S. pneumoniae</i> comprising administering of vaccine compositions.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30390

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/09 A61K39/40 A61P31/04 //C07K14/315

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

STRAND, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 18930 A (HUMAN GENOME SCIENCES INC ;CHOI GIL H (US); HROMOCKYJ ALEX (US); J) 7 May 1998 (1998-05-07) page 59 -page 60 page 4, line 14 -page 5, line 16 ---	1-3
P,X	WO 99 15675 A (GREEN BRUCE A ;CHENG QI (US); FINKEL DAVID J (US); MASI AMY W (US)) 1 April 1999 (1999-04-01) claims 50-52,55-59 page 18, line 21 -page 19, line 12 --- -/--	1-3

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

10 August 2000

Date of mailing of the international search report

17/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Covone, M

# INTERNATIONAL SEARCH REPORT

In: International Application No  
PCT/US 99/30390

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 00 06737 A (GILBERT CHRISTOPHE FRANCOIS GU ; HANSBRO PHILIP MICHAEL (GB); MICRO) 10 February 2000 (2000-02-10) page 2, line 10-12 page 13, line 9 -page 14, line 23 overlap seq.Id 6 page 76, line 31-38 overlap seq.Id 4,10 page 99 -page 100</p> <p>-----</p>	1-3

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/30390

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9818930 A	07-05-1998	AU 5194598 A	22-05-1998
		AU 6909098 A	22-05-1998
		EP 0942983 A	22-09-1999
		EP 0941335 A	15-09-1999
		WO 9818931 A	07-05-1998
WO 9915675 A	01-04-1999	AU 2420800 A	15-06-2000
		AU 9510598 A	12-04-1999
		EP 1017828 A	12-07-2000
WO 0006737 A	10-02-2000	NONE	

